BRPI0616146A2 - derivados benzotiazol ciclobutil amina e seu uso como ligantes dos receptores de histamina-3 - Google Patents

derivados benzotiazol ciclobutil amina e seu uso como ligantes dos receptores de histamina-3 Download PDF

Info

Publication number: BRPI0616146A2
Authority: BR; Brazil
Prior art keywords: cyclobutyl; trans; benzothiazol; benzothiazole; piperidin
Prior art date: 2005-09-22

Application number

BRPI0616146-4A

Other languages

English (en)

Portuguese (pt)

Inventor

Marlon D Cowart

Minghua Sun

Chen Zhao

Guo Zhu Zheng

Original Assignee

Abbott Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-22

Filing date

2006-09-19

Publication date

2011-06-07

2006-09-19 Application filed by Abbott Lab filed Critical Abbott Lab

2011-06-07 Publication of BRPI0616146A2 publication Critical patent/BRPI0616146A2/pt

Links

-1 benzothiazole cyclobutyl amine derivatives Chemical class 0.000 title claims description 360
239000011230 binding agent Substances 0.000 title description 11
IOJUPLGTWVMSFF-UHFFFAOYSA-N cyclobenzothiazole Natural products C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 title description 6
150000001875 compounds Chemical class 0.000 claims abstract description 497
238000000034 method Methods 0.000 claims abstract description 241
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 140
125000000217 alkyl group Chemical group 0.000 claims description 69
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 65
229910052739 hydrogen Inorganic materials 0.000 claims description 52
239000001257 hydrogen Substances 0.000 claims description 51
AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical compound OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 claims description 43
239000002253 acid Substances 0.000 claims description 43
125000000623 heterocyclic group Chemical group 0.000 claims description 42
150000002431 hydrogen Chemical group 0.000 claims description 41
125000003118 aryl group Chemical group 0.000 claims description 39
125000000753 cycloalkyl group Chemical group 0.000 claims description 36
229910052757 nitrogen Inorganic materials 0.000 claims description 35
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 31
125000003545 alkoxy group Chemical group 0.000 claims description 31
LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
229910003827 NRaRb Inorganic materials 0.000 claims description 25
125000004183 alkoxy alkyl group Chemical group 0.000 claims description 25
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
125000004093 cyano group Chemical group *C#N 0.000 claims description 23
230000000694 effects Effects 0.000 claims description 23
150000001412 amines Chemical class 0.000 claims description 21
208000035475 disorder Diseases 0.000 claims description 21
150000002148 esters Chemical class 0.000 claims description 21
125000001424 substituent group Chemical group 0.000 claims description 21
125000002252 acyl group Chemical group 0.000 claims description 19
125000004414 alkyl thio group Chemical group 0.000 claims description 19
229910052736 halogen Inorganic materials 0.000 claims description 19
150000002367 halogens Chemical class 0.000 claims description 19
125000002768 hydroxyalkyl group Chemical group 0.000 claims description 19
150000003839 salts Chemical class 0.000 claims description 19
229910052799 carbon Inorganic materials 0.000 claims description 18
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 17
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 17
125000001188 haloalkyl group Chemical group 0.000 claims description 17
125000004433 nitrogen atom Chemical group N* 0.000 claims description 17
125000004448 alkyl carbonyl group Chemical group 0.000 claims description 16
125000006574 non-aromatic ring group Chemical group 0.000 claims description 16
229920002472 Starch Chemical group 0.000 claims description 14
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 14
125000001072 heteroaryl group Chemical group 0.000 claims description 14
235000019698 starch Nutrition 0.000 claims description 14
125000003342 alkenyl group Chemical group 0.000 claims description 13
125000002947 alkylene group Chemical group 0.000 claims description 13
150000001408 amides Chemical class 0.000 claims description 13
229910052760 oxygen Inorganic materials 0.000 claims description 13
UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims description 13
125000004423 acyloxy group Chemical group 0.000 claims description 12
125000005083 alkoxyalkoxy group Chemical group 0.000 claims description 12
239000008107 starch Chemical group 0.000 claims description 12
229910052717 sulfur Inorganic materials 0.000 claims description 12
125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 11
125000004438 haloalkoxy group Chemical group 0.000 claims description 11
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 11
201000000980 schizophrenia Diseases 0.000 claims description 11
125000000676 alkoxyimino group Chemical group 0.000 claims description 10
125000005138 alkoxysulfonyl group Chemical group 0.000 claims description 10
TXWOGHSRPAYOML-UHFFFAOYSA-N cyclobutanecarboxylic acid Chemical compound OC(=O)C1CCC1 TXWOGHSRPAYOML-UHFFFAOYSA-N 0.000 claims description 10
125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 10
125000000719 pyrrolidinyl group Chemical group 0.000 claims description 10
125000003396 thiol group Chemical class [H]S* 0.000 claims description 10
125000004432 carbon atom Chemical group C* 0.000 claims description 9
125000003226 pyrazolyl group Chemical group 0.000 claims description 9
125000004076 pyridyl group Chemical group 0.000 claims description 9
125000000714 pyrimidinyl group Chemical group 0.000 claims description 9
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
125000000304 alkynyl group Chemical group 0.000 claims description 8
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
239000003937 drug carrier Substances 0.000 claims description 8
125000001425 triazolyl group Chemical group 0.000 claims description 8
125000002393 azetidinyl group Chemical group 0.000 claims description 7
NIPZZXUFJPQHNH-UHFFFAOYSA-N pyrazine-2-carboxylic acid Chemical compound OC(=O)C1=CN=CC=N1 NIPZZXUFJPQHNH-UHFFFAOYSA-N 0.000 claims description 7
125000001422 pyrrolinyl group Chemical group 0.000 claims description 7
125000000168 pyrrolyl group Chemical group 0.000 claims description 7
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 7
125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 6
ABXPYCIUPKSNPM-XSRFYTQQSA-N 6-bromo-2-[3-[(2r)-2-methylpyrrolidin-1-yl]cyclobutyl]-1,3-benzothiazole Chemical compound C[C@@H]1CCCN1C1CC(C=2SC3=CC(Br)=CC=C3N=2)C1 ABXPYCIUPKSNPM-XSRFYTQQSA-N 0.000 claims description 6
206010010904 Convulsion Diseases 0.000 claims description 6
125000004069 aziridinyl group Chemical group 0.000 claims description 6
230000007278 cognition impairment Effects 0.000 claims description 6
125000002757 morpholinyl group Chemical group 0.000 claims description 6
125000004193 piperazinyl group Chemical group 0.000 claims description 6
125000003386 piperidinyl group Chemical group 0.000 claims description 6
125000003373 pyrazinyl group Chemical group 0.000 claims description 6
125000002098 pyridazinyl group Chemical group 0.000 claims description 6
125000005494 pyridonyl group Chemical group 0.000 claims description 6
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
YUXZYOIYOWPNBW-JEYLPNPQSA-N 6-(2,4-dimethoxypyrimidin-5-yl)-2-[3-[(2s)-2-methylpyrrolidin-1-yl]cyclobutyl]-1,3-benzothiazole Chemical compound COC1=NC(OC)=NC=C1C1=CC=C(N=C(S2)C3CC(C3)N3[C@H](CCC3)C)C2=C1 YUXZYOIYOWPNBW-JEYLPNPQSA-N 0.000 claims description 5
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 5
241000124008 Mammalia Species 0.000 claims description 5
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 5
125000003725 azepanyl group Chemical group 0.000 claims description 5
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 5
208000010877 cognitive disease Diseases 0.000 claims description 5
BAVYZALUXZFZLV-UHFFFAOYSA-N mono-methylamine Natural products NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 5
208000011580 syndromic disease Diseases 0.000 claims description 5
125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims description 4
208000024827 Alzheimer disease Diseases 0.000 claims description 4
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 4
OVDHIDWLHHCHDB-CTYIDZIISA-N C1CN(C1)[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-c1cncnc1 Chemical compound C1CN(C1)[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-c1cncnc1 OVDHIDWLHHCHDB-CTYIDZIISA-N 0.000 claims description 4
BNNXTGQYDDNTHG-KOMQPUFPSA-N C1[C@@H](C[C@H]1c1nc2ccc(cc2s1)-c1cncnc1)N1CCCC1 Chemical compound C1[C@@H](C[C@H]1c1nc2ccc(cc2s1)-c1cncnc1)N1CCCC1 BNNXTGQYDDNTHG-KOMQPUFPSA-N 0.000 claims description 4
FPIOZVJJQMCVFX-JCNLHEQBSA-N C1[C@@H](C[C@H]1c1nc2ccc(cc2s1)-c1cncnc1)N1CCCCC1 Chemical compound C1[C@@H](C[C@H]1c1nc2ccc(cc2s1)-c1cncnc1)N1CCCCC1 FPIOZVJJQMCVFX-JCNLHEQBSA-N 0.000 claims description 4
GYWCHNSDHIJRPI-ATZDWAIDSA-N C[C@@H]1CCCN1[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-c1ccc(C)nc1C Chemical compound C[C@@H]1CCCN1[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-c1ccc(C)nc1C GYWCHNSDHIJRPI-ATZDWAIDSA-N 0.000 claims description 4
RINYBFJVYSKATO-XIRDDKMYSA-N FC[C@@H]1CCCN1[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-c1cncnc1 Chemical compound FC[C@@H]1CCCN1[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-c1cncnc1 RINYBFJVYSKATO-XIRDDKMYSA-N 0.000 claims description 4
208000026139 Memory disease Diseases 0.000 claims description 4
CLVPOZCCNGMQSL-AULYBMBSSA-N N1(CCCCC1)[C@@H]1C[C@H](C1)C=1SC2=C(N1)C=CC(=C2)N Chemical compound N1(CCCCC1)[C@@H]1C[C@H](C1)C=1SC2=C(N1)C=CC(=C2)N CLVPOZCCNGMQSL-AULYBMBSSA-N 0.000 claims description 4
TUQJMUVOHBTCKY-KOMQPUFPSA-N O=c1cccnn1-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCC1 Chemical compound O=c1cccnn1-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCC1 TUQJMUVOHBTCKY-KOMQPUFPSA-N 0.000 claims description 4
AIHXBSPGERDVJQ-SAABIXHNSA-N OCC1CCN(CC1)[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-c1cncnc1 Chemical compound OCC1CCN(CC1)[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-c1cncnc1 AIHXBSPGERDVJQ-SAABIXHNSA-N 0.000 claims description 4
208000008589 Obesity Diseases 0.000 claims description 4
208000006673 asthma Diseases 0.000 claims description 4
208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 4
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 4
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
125000004802 cyanophenyl group Chemical group 0.000 claims description 4
206010013663 drug dependence Diseases 0.000 claims description 4
206010015037 epilepsy Diseases 0.000 claims description 4
125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 4
125000002541 furyl group Chemical group 0.000 claims description 4
125000000592 heterocycloalkyl group Chemical group 0.000 claims description 4
125000002883 imidazolyl group Chemical group 0.000 claims description 4
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 4
125000001041 indolyl group Chemical group 0.000 claims description 4
125000001786 isothiazolyl group Chemical group 0.000 claims description 4
125000000842 isoxazolyl group Chemical group 0.000 claims description 4
235000020824 obesity Nutrition 0.000 claims description 4
125000002971 oxazolyl group Chemical group 0.000 claims description 4
IIVUJUOJERNGQX-UHFFFAOYSA-N pyrimidine-5-carboxylic acid Chemical compound OC(=O)C1=CN=CN=C1 IIVUJUOJERNGQX-UHFFFAOYSA-N 0.000 claims description 4
208000011117 substance-related disease Diseases 0.000 claims description 4
125000003831 tetrazolyl group Chemical group 0.000 claims description 4
125000004306 triazinyl group Chemical group 0.000 claims description 4
JCZAVVUIFWZMQI-UHFFFAOYSA-N 1h-thieno[2,3-d]imidazole Chemical compound N1C=NC2=C1C=CS2 JCZAVVUIFWZMQI-UHFFFAOYSA-N 0.000 claims description 3
VDVJQFLGCFFFBP-UHFFFAOYSA-N 2,3-dihydropyrrole-1-carboxylic acid Chemical compound OC(=O)N1CCC=C1 VDVJQFLGCFFFBP-UHFFFAOYSA-N 0.000 claims description 3
HUOAEBFRBWKTQE-UHFFFAOYSA-N 2-(2-methoxypyrimidin-5-yl)-1,3-benzothiazole Chemical compound C1=NC(OC)=NC=C1C1=NC2=CC=CC=C2S1 HUOAEBFRBWKTQE-UHFFFAOYSA-N 0.000 claims description 3
CLVPOZCCNGMQSL-UHFFFAOYSA-N 2-(3-piperidin-1-ylcyclobutyl)-1,3-benzothiazol-6-amine Chemical compound S1C2=CC(N)=CC=C2N=C1C(C1)CC1N1CCCCC1 CLVPOZCCNGMQSL-UHFFFAOYSA-N 0.000 claims description 3
CVEBXWMUCRDRQP-UHFFFAOYSA-N 2-(3-piperidin-1-ylcyclobutyl)-n-pyrimidin-5-yl-1,3-benzothiazol-6-amine Chemical compound C1C(N2CCCCC2)CC1C(SC1=C2)=NC1=CC=C2NC1=CN=CN=C1 CVEBXWMUCRDRQP-UHFFFAOYSA-N 0.000 claims description 3
UATBYRPUSAQAML-UHFFFAOYSA-N 6-pyrimidin-5-yl-2-[3-(pyrrolidin-1-ylmethyl)cyclobutyl]-1,3-benzothiazole Chemical compound C1CCCN1CC(C1)CC1C(SC1=C2)=NC1=CC=C2C1=CN=CN=C1 UATBYRPUSAQAML-UHFFFAOYSA-N 0.000 claims description 3
UGYKZEQGXFGOFK-UMSPYCQHSA-N Brc1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCOCC1 Chemical compound Brc1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCOCC1 UGYKZEQGXFGOFK-UMSPYCQHSA-N 0.000 claims description 3
NLZOPDAUVGPKSU-IYARVYRRSA-N CC(C)N(C)[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-c1ccc(C)nc1C Chemical compound CC(C)N(C)[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-c1ccc(C)nc1C NLZOPDAUVGPKSU-IYARVYRRSA-N 0.000 claims description 3
PFMYDYAENBOLIX-CTYIDZIISA-N CCC(=O)Nc1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCC1 Chemical compound CCC(=O)Nc1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCC1 PFMYDYAENBOLIX-CTYIDZIISA-N 0.000 claims description 3
UAHKNQIMPCQKNZ-KOMQPUFPSA-N CCN(CC)[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-c1cncnc1 Chemical compound CCN(CC)[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-c1cncnc1 UAHKNQIMPCQKNZ-KOMQPUFPSA-N 0.000 claims description 3
PIOWPPYTJUAIPA-QAQDUYKDSA-N COc1ccc(cn1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCC1 Chemical compound COc1ccc(cn1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCC1 PIOWPPYTJUAIPA-QAQDUYKDSA-N 0.000 claims description 3
KVBGRLIOEMFCGG-SHTZXODSSA-N COc1ncc(-c2ccc3nc(sc3c2)[C@H]2C[C@@H](C2)N2CCCC2)c(OC)n1 Chemical compound COc1ncc(-c2ccc3nc(sc3c2)[C@H]2C[C@@H](C2)N2CCCC2)c(OC)n1 KVBGRLIOEMFCGG-SHTZXODSSA-N 0.000 claims description 3
YUXZYOIYOWPNBW-FVQBIDKESA-N COc1ncc(-c2ccc3nc(sc3c2)[C@H]2C[C@@H](C2)N2CCC[C@H]2C)c(OC)n1 Chemical compound COc1ncc(-c2ccc3nc(sc3c2)[C@H]2C[C@@H](C2)N2CCC[C@H]2C)c(OC)n1 YUXZYOIYOWPNBW-FVQBIDKESA-N 0.000 claims description 3
CGEXIEBOQFSPNA-QBIRGWOPSA-N COc1ncc(-c2ccc3sc(nc3c2)[C@H]2C[C@@H](C2)N2CCCC2C)c(OC)n1 Chemical compound COc1ncc(-c2ccc3sc(nc3c2)[C@H]2C[C@@H](C2)N2CCCC2C)c(OC)n1 CGEXIEBOQFSPNA-QBIRGWOPSA-N 0.000 claims description 3
ULWIEYDEGDJIKF-CTYIDZIISA-N COc1ncc(cn1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCC1 Chemical compound COc1ncc(cn1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCC1 ULWIEYDEGDJIKF-CTYIDZIISA-N 0.000 claims description 3
KYFPYVFHSPDPNE-QRTARXTBSA-N COc1ncc(cn1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCC[C@@H]1C Chemical compound COc1ncc(cn1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCC[C@@H]1C KYFPYVFHSPDPNE-QRTARXTBSA-N 0.000 claims description 3
KOJMRFBMBQKHAR-KBRIMQKVSA-N C[C@@H]1CCCN1[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-c1ccc(F)nc1 Chemical compound C[C@@H]1CCCN1[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-c1ccc(F)nc1 KOJMRFBMBQKHAR-KBRIMQKVSA-N 0.000 claims description 3
FTUQXSFFPKHOES-CDHQVMDDSA-N C[C@@H]1CCCN1[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-c1ccc(cc1)C#N Chemical compound C[C@@H]1CCCN1[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-c1ccc(cc1)C#N FTUQXSFFPKHOES-CDHQVMDDSA-N 0.000 claims description 3
RTAZDITWLJGILQ-ZTFGCOKTSA-N C[C@@H]1CCCN1[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-c1cccnc1 Chemical compound C[C@@H]1CCCN1[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-c1cccnc1 RTAZDITWLJGILQ-ZTFGCOKTSA-N 0.000 claims description 3
GPHCGUDDNZDFPX-FRFSOERESA-N C[C@@H]1CCCN1[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-c1cncnc1 Chemical compound C[C@@H]1CCCN1[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-c1cncnc1 GPHCGUDDNZDFPX-FRFSOERESA-N 0.000 claims description 3
ZKBQMQLPLNMETD-QAQDUYKDSA-N Cc1ccc(-c2ccc3nc(sc3c2)[C@H]2C[C@@H](C2)N2CCC2)c(C)n1 Chemical compound Cc1ccc(-c2ccc3nc(sc3c2)[C@H]2C[C@@H](C2)N2CCC2)c(C)n1 ZKBQMQLPLNMETD-QAQDUYKDSA-N 0.000 claims description 3
FFZWFUCMEGSIIH-JCNLHEQBSA-N Cc1ccc(=O)n(n1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCC1 Chemical compound Cc1ccc(=O)n(n1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCC1 FFZWFUCMEGSIIH-JCNLHEQBSA-N 0.000 claims description 3
SZEMFQGOXCYFRG-CTYIDZIISA-N Cn1cc(cn1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCC1 Chemical compound Cn1cc(cn1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCC1 SZEMFQGOXCYFRG-CTYIDZIISA-N 0.000 claims description 3
MJOAVRCBZWPHKF-SAABIXHNSA-N Cn1cc(cn1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCCC1 Chemical compound Cn1cc(cn1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCCC1 MJOAVRCBZWPHKF-SAABIXHNSA-N 0.000 claims description 3
208000027530 Meniere disease Diseases 0.000 claims description 3
208000002193 Pain Diseases 0.000 claims description 3
208000018737 Parkinson disease Diseases 0.000 claims description 3
125000004190 benzothiazol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N=C(*)SC2=C1[H] 0.000 claims description 3
230000006735 deficit Effects 0.000 claims description 3
206010012601 diabetes mellitus Diseases 0.000 claims description 3
125000005056 dihydrothiazolyl group Chemical group S1C(NC=C1)* 0.000 claims description 3
208000002173 dizziness Diseases 0.000 claims description 3
229910052731 fluorine Inorganic materials 0.000 claims description 3
AQYSYJUIMQTRMV-UHFFFAOYSA-N hypofluorous acid Chemical compound FO AQYSYJUIMQTRMV-UHFFFAOYSA-N 0.000 claims description 3
230000013016 learning Effects 0.000 claims description 3
201000001441 melanoma Diseases 0.000 claims description 3
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims description 3
201000003631 narcolepsy Diseases 0.000 claims description 3
208000020016 psychiatric disease Diseases 0.000 claims description 3
229910052705 radium Inorganic materials 0.000 claims description 3
229910052701 rubidium Inorganic materials 0.000 claims description 3
208000019116 sleep disease Diseases 0.000 claims description 3
208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 3
JTPZTKBRUCILQD-UHFFFAOYSA-N 1-methylimidazolidin-2-one Chemical compound CN1CCNC1=O JTPZTKBRUCILQD-UHFFFAOYSA-N 0.000 claims description 2
NZFJFJBOZAMZPY-UHFFFAOYSA-N 2-(3-pyrrolidin-1-ylcyclobutyl)-1,3-benzothiazole Chemical compound N1(CCCC1)C1CC(C1)C=1SC2=C(N=1)C=CC=C2 NZFJFJBOZAMZPY-UHFFFAOYSA-N 0.000 claims description 2
QBLLOOKBLTTXHB-UHFFFAOYSA-N 4-fluoropiperidine Chemical compound FC1CCNCC1 QBLLOOKBLTTXHB-UHFFFAOYSA-N 0.000 claims description 2
208000020925 Bipolar disease Diseases 0.000 claims description 2
NQDHJJFOCWHDFN-KOMQPUFPSA-N CC(C)C(=O)Nc1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCC1 Chemical compound CC(C)C(=O)Nc1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCC1 NQDHJJFOCWHDFN-KOMQPUFPSA-N 0.000 claims description 2
MTFYICBRVOCJMP-JCNLHEQBSA-N CC(C)N(C)[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-n1cccc(C)c1=O Chemical compound CC(C)N(C)[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-n1cccc(C)c1=O MTFYICBRVOCJMP-JCNLHEQBSA-N 0.000 claims description 2
BCZICRAWEHGIEX-UMSPYCQHSA-N CCCN(C)[C@H]1C[C@@H](C1)c1nc2ccc(Br)cc2s1 Chemical compound CCCN(C)[C@H]1C[C@@H](C1)c1nc2ccc(Br)cc2s1 BCZICRAWEHGIEX-UMSPYCQHSA-N 0.000 claims description 2
ZJMANYSQEOSNNB-IYARVYRRSA-N COc1ccc(cn1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCC1 Chemical compound COc1ccc(cn1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCC1 ZJMANYSQEOSNNB-IYARVYRRSA-N 0.000 claims description 2
BORQIBSWTPRMTR-WBAXXEDZSA-N COc1ccc(cn1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCC[C@@H]1C Chemical compound COc1ccc(cn1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCC[C@@H]1C BORQIBSWTPRMTR-WBAXXEDZSA-N 0.000 claims description 2
MPYIARDVAGNTPP-IYARVYRRSA-N Cc1ccc(c(C)n1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCC1 Chemical compound Cc1ccc(c(C)n1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCC1 MPYIARDVAGNTPP-IYARVYRRSA-N 0.000 claims description 2
GFCKGOPDXAAEBT-WGSAOQKQSA-N Cc1ccc(c(C)n1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCC1 Chemical compound Cc1ccc(c(C)n1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCC1 GFCKGOPDXAAEBT-WGSAOQKQSA-N 0.000 claims description 2
206010012289 Dementia Diseases 0.000 claims description 2
PIHXCRPKUMOBPD-MJHDQNEOSA-N FC1CCN(CC1)[C@H]1C[C@@H](C1)c1nc2ccc(Br)cc2s1 Chemical compound FC1CCN(CC1)[C@H]1C[C@@H](C1)c1nc2ccc(Br)cc2s1 PIHXCRPKUMOBPD-MJHDQNEOSA-N 0.000 claims description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
206010061218 Inflammation Diseases 0.000 claims description 2
208000037196 Medullary thyroid carcinoma Diseases 0.000 claims description 2
208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
PPAVXOQXHZHRKZ-JCNLHEQBSA-N O=C(Nc1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCC1)N1CCOCC1 Chemical compound O=C(Nc1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCC1)N1CCOCC1 PPAVXOQXHZHRKZ-JCNLHEQBSA-N 0.000 claims description 2
208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 2
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
CPPKAGUPTKIMNP-UHFFFAOYSA-N cyanogen fluoride Chemical compound FC#N CPPKAGUPTKIMNP-UHFFFAOYSA-N 0.000 claims description 2
239000011737 fluorine Substances 0.000 claims description 2
230000004054 inflammatory process Effects 0.000 claims description 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims description 2
125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 2
HVVNJUAVDAZWCB-UHFFFAOYSA-N prolinol Chemical compound OCC1CCCN1 HVVNJUAVDAZWCB-UHFFFAOYSA-N 0.000 claims description 2
239000002287 radioligand Substances 0.000 claims description 2
BSXLLFUSNQCWJP-UHFFFAOYSA-N thiophene-2-sulfonic acid Chemical compound OS(=O)(=O)C1=CC=CS1 BSXLLFUSNQCWJP-UHFFFAOYSA-N 0.000 claims description 2
208000013818 thyroid gland medullary carcinoma Diseases 0.000 claims description 2
NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 claims 4
OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 claims 2
SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 claims 2
VZFUCHSFHOYXIS-UHFFFAOYSA-N cycloheptane carboxylic acid Natural products OC(=O)C1CCCCCC1 VZFUCHSFHOYXIS-UHFFFAOYSA-N 0.000 claims 2
JBDSSBMEKXHSJF-UHFFFAOYSA-N cyclopentanecarboxylic acid Chemical compound OC(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-N 0.000 claims 2
125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
YLZYSVYZMDJYOT-UHFFFAOYSA-N 2-methoxypyrimidine Chemical compound COC1=NC=CC=N1 YLZYSVYZMDJYOT-UHFFFAOYSA-N 0.000 claims 1
208000018522 Gastrointestinal disease Diseases 0.000 claims 1
102000004877 Insulin Human genes 0.000 claims 1
108090001061 Insulin Proteins 0.000 claims 1
241000764238 Isis Species 0.000 claims 1
208000019695 Migraine disease Diseases 0.000 claims 1
206010028813 Nausea Diseases 0.000 claims 1
208000007920 Neurogenic Inflammation Diseases 0.000 claims 1
IMEQKRCWRGUZPG-KESTWPANSA-N O=C(Nc1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCC1)c1ccc(cc1)C#N Chemical compound O=C(Nc1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCC1)c1ccc(cc1)C#N IMEQKRCWRGUZPG-KESTWPANSA-N 0.000 claims 1
206010040070 Septic Shock Diseases 0.000 claims 1
206010000891 acute myocardial infarction Diseases 0.000 claims 1
229910000272 alkali metal oxide Inorganic materials 0.000 claims 1
KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims 1
RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 1
229940125396 insulin Drugs 0.000 claims 1
206010027599 migraine Diseases 0.000 claims 1
230000036651 mood Effects 0.000 claims 1
230000008693 nausea Effects 0.000 claims 1
229940080818 propionamide Drugs 0.000 claims 1
230000036303 septic shock Effects 0.000 claims 1
201000000849 skin cancer Diseases 0.000 claims 1
201000008261 skin carcinoma Diseases 0.000 claims 1
KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 95
239000003446 ligand Substances 0.000 abstract description 13
238000004519 manufacturing process Methods 0.000 abstract description 2
230000001668 ameliorated effect Effects 0.000 abstract 1
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 347
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 213
238000005160 1H NMR spectroscopy Methods 0.000 description 201
239000000047 product Substances 0.000 description 198
239000000243 solution Substances 0.000 description 48
KLKWZMKGTIQLOG-UHFFFAOYSA-N [3-fluoro-5-(2-methylpropoxy)phenyl]boronic acid Chemical compound CC(C)COC1=CC(F)=CC(B(O)O)=C1 KLKWZMKGTIQLOG-UHFFFAOYSA-N 0.000 description 45
238000006467 substitution reaction Methods 0.000 description 43
238000006243 chemical reaction Methods 0.000 description 38
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
102000004384 Histamine H3 receptors Human genes 0.000 description 34
108090000981 Histamine H3 receptors Proteins 0.000 description 34
239000003814 drug Substances 0.000 description 34
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 32
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 30
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 28
239000012346 acetyl chloride Substances 0.000 description 28
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 27
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 26
238000011282 treatment Methods 0.000 description 26
239000012043 crude product Substances 0.000 description 25
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 23
229940079593 drug Drugs 0.000 description 23
239000012044 organic layer Substances 0.000 description 23
102000005962 receptors Human genes 0.000 description 23
108020003175 receptors Proteins 0.000 description 23
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 22
239000000908 ammonium hydroxide Substances 0.000 description 22
239000007787 solid Substances 0.000 description 22
239000000460 chlorine Substances 0.000 description 21
OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 20
239000002585 base Substances 0.000 description 20
239000002904 solvent Substances 0.000 description 20
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 19
238000004440 column chromatography Methods 0.000 description 19
125000002887 hydroxy group Chemical group [H]O* 0.000 description 19
229910052938 sodium sulfate Inorganic materials 0.000 description 19
235000011152 sodium sulphate Nutrition 0.000 description 19
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 18
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
239000012267 brine Substances 0.000 description 18
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 18
OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 16
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
229910052794 bromium Inorganic materials 0.000 description 16
NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 15
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
239000003395 histamine H3 receptor antagonist Substances 0.000 description 15
210000004556 brain Anatomy 0.000 description 14
238000002360 preparation method Methods 0.000 description 14
230000002829 reductive effect Effects 0.000 description 14
YPWAJLGHACDYQS-UHFFFAOYSA-N (2-methoxypyrimidin-5-yl)boronic acid Chemical compound COC1=NC=C(B(O)O)C=N1 YPWAJLGHACDYQS-UHFFFAOYSA-N 0.000 description 13
239000003153 chemical reaction reagent Substances 0.000 description 13
229960001340 histamine Drugs 0.000 description 13
229910052740 iodine Inorganic materials 0.000 description 13
KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 13
229910000027 potassium carbonate Inorganic materials 0.000 description 13
238000011160 research Methods 0.000 description 13
238000004809 thin layer chromatography Methods 0.000 description 13
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 12
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
239000003921 oil Substances 0.000 description 11
235000019198 oils Nutrition 0.000 description 11
238000002600 positron emission tomography Methods 0.000 description 11
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
230000027455 binding Effects 0.000 description 10
150000001721 carbon Chemical group 0.000 description 10
238000002844 melting Methods 0.000 description 10
230000008018 melting Effects 0.000 description 10
239000011734 sodium Substances 0.000 description 10
239000000126 substance Substances 0.000 description 10
238000003786 synthesis reaction Methods 0.000 description 10
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 9
229910021529 ammonia Inorganic materials 0.000 description 9
125000004429 atom Chemical group 0.000 description 9
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 9
235000019441 ethanol Nutrition 0.000 description 9
239000001301 oxygen Chemical group 0.000 description 9
239000000843 powder Substances 0.000 description 9
239000011541 reaction mixture Substances 0.000 description 9
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 9
239000011593 sulfur Chemical group 0.000 description 9
241001465754 Metazoa Species 0.000 description 8
241000700159 Rattus Species 0.000 description 8
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical compound O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 8
238000004587 chromatography analysis Methods 0.000 description 8
230000019771 cognition Effects 0.000 description 8
235000019439 ethyl acetate Nutrition 0.000 description 8
150000004820 halides Chemical class 0.000 description 8
238000010438 heat treatment Methods 0.000 description 8
239000002502 liposome Substances 0.000 description 8
229910052751 metal Inorganic materials 0.000 description 8
239000002184 metal Substances 0.000 description 8
230000000144 pharmacologic effect Effects 0.000 description 8
MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 8
238000003756 stirring Methods 0.000 description 8
RGHPCLZJAFCTIK-RXMQYKEDSA-N (R)-2-methylpyrrolidine Chemical group C[C@@H]1CCCN1 RGHPCLZJAFCTIK-RXMQYKEDSA-N 0.000 description 7
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
229940115480 Histamine H3 receptor antagonist Drugs 0.000 description 7
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 7
125000002619 bicyclic group Chemical group 0.000 description 7
229910052801 chlorine Inorganic materials 0.000 description 7
231100000252 nontoxic Toxicity 0.000 description 7
230000003000 nontoxic effect Effects 0.000 description 7
239000000651 prodrug Substances 0.000 description 7
229940002612 prodrug Drugs 0.000 description 7
229910002027 silica gel Inorganic materials 0.000 description 7
239000000741 silica gel Substances 0.000 description 7
QZWIXLPWMGHDDD-UHFFFAOYSA-N 3-methyl-1h-pyridazin-6-one Chemical compound CC1=CC=C(O)N=N1 QZWIXLPWMGHDDD-UHFFFAOYSA-N 0.000 description 6
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 6
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
239000000556 agonist Substances 0.000 description 6
239000005557 antagonist Substances 0.000 description 6
230000003542 behavioural effect Effects 0.000 description 6
239000003054 catalyst Substances 0.000 description 6
NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 6
125000005842 heteroatom Chemical group 0.000 description 6
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
239000007788 liquid Substances 0.000 description 6
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 6
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
229920001223 polyethylene glycol Polymers 0.000 description 6
230000003389 potentiating effect Effects 0.000 description 6
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
230000008569 process Effects 0.000 description 6
238000000746 purification Methods 0.000 description 6
WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 6
BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 6
MVKDNXIKAWKCCS-UHFFFAOYSA-N 3-methyl-1h-pyridin-2-one Chemical compound CC1=CC=CN=C1O MVKDNXIKAWKCCS-UHFFFAOYSA-N 0.000 description 5
ZRWMAMOBIQQJSA-UHFFFAOYSA-N 3-methylidenecyclobutane-1-carbonitrile Chemical compound C=C1CC(C#N)C1 ZRWMAMOBIQQJSA-UHFFFAOYSA-N 0.000 description 5
SOHMZGMHXUQHGE-UHFFFAOYSA-N 5-methyl-1h-pyridin-2-one Chemical compound CC1=CC=C(O)N=C1 SOHMZGMHXUQHGE-UHFFFAOYSA-N 0.000 description 5
229910021595 Copper(I) iodide Inorganic materials 0.000 description 5
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
102000000543 Histamine Receptors Human genes 0.000 description 5
108010002059 Histamine Receptors Proteins 0.000 description 5
241000282412 Homo Species 0.000 description 5
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
238000005481 NMR spectroscopy Methods 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
239000007984 Tris EDTA buffer Substances 0.000 description 5
230000008901 benefit Effects 0.000 description 5
MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 5
ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 5
238000009472 formulation Methods 0.000 description 5
230000000742 histaminergic effect Effects 0.000 description 5
150000002430 hydrocarbons Chemical group 0.000 description 5
239000000463 material Substances 0.000 description 5
230000001537 neural effect Effects 0.000 description 5
229910052763 palladium Inorganic materials 0.000 description 5
YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 5
239000003755 preservative agent Substances 0.000 description 5
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
229910052708 sodium Inorganic materials 0.000 description 5
239000000725 suspension Substances 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
239000003981 vehicle Substances 0.000 description 5
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
NNWUEBIEOFQMSS-UHFFFAOYSA-N 2-Methylpiperidine Chemical compound CC1CCCCN1 NNWUEBIEOFQMSS-UHFFFAOYSA-N 0.000 description 4
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
QKDDJDBFONZGBW-UHFFFAOYSA-N N-Cyclohexy-4-(imidazol-4-yl)-1-piperidinecarbothioamide Chemical compound C1CC(C=2NC=NC=2)CCN1C(=S)NC1CCCCC1 QKDDJDBFONZGBW-UHFFFAOYSA-N 0.000 description 4
BLDYQXDJIDCRDG-AULYBMBSSA-N N1([C@H]2C[C@@H](C2)C2=NC3=CC=C(C=C3S2)Br)CCCCC1 Chemical compound N1([C@H]2C[C@@H](C2)C2=NC3=CC=C(C=C3S2)Br)CCCCC1 BLDYQXDJIDCRDG-AULYBMBSSA-N 0.000 description 4
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
238000006069 Suzuki reaction reaction Methods 0.000 description 4
239000007983 Tris buffer Substances 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
150000007513 acids Chemical class 0.000 description 4
235000010443 alginic acid Nutrition 0.000 description 4
229920000615 alginic acid Polymers 0.000 description 4
208000026935 allergic disease Diseases 0.000 description 4
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 4
239000002775 capsule Substances 0.000 description 4
125000002843 carboxylic acid group Chemical group 0.000 description 4
210000003169 central nervous system Anatomy 0.000 description 4
238000012512 characterization method Methods 0.000 description 4
229910052802 copper Inorganic materials 0.000 description 4
239000010949 copper Substances 0.000 description 4
238000011161 development Methods 0.000 description 4
201000010099 disease Diseases 0.000 description 4
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 4
238000001914 filtration Methods 0.000 description 4
230000007062 hydrolysis Effects 0.000 description 4
238000006460 hydrolysis reaction Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
238000010348 incorporation Methods 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000004006 olive oil Substances 0.000 description 4
235000008390 olive oil Nutrition 0.000 description 4
125000004043 oxo group Chemical group O=* 0.000 description 4
125000004430 oxygen atom Chemical group O* 0.000 description 4
LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 4
239000002245 particle Substances 0.000 description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
239000006187 pill Substances 0.000 description 4
230000002035 prolonged effect Effects 0.000 description 4
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 description 4
238000001953 recrystallisation Methods 0.000 description 4
229920006395 saturated elastomer Polymers 0.000 description 4
239000007921 spray Substances 0.000 description 4
QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 description 4
230000009466 transformation Effects 0.000 description 4
239000001993 wax Substances 0.000 description 4
239000000080 wetting agent Substances 0.000 description 4
CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 4
DHADXDMPEUWEAS-UHFFFAOYSA-N (6-methoxypyridin-3-yl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=N1 DHADXDMPEUWEAS-UHFFFAOYSA-N 0.000 description 3
ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 3
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
229920001817 Agar Polymers 0.000 description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
241000416162 Astragalus gummifer Species 0.000 description 3
239000005711 Benzoic acid Substances 0.000 description 3
IUYCHWWTZJSDJO-SAABIXHNSA-N C1[C@@H](C[C@H]1c1nc2ccc(cc2s1)-c1cncnc1)N1CCCCCC1 Chemical compound C1[C@@H](C[C@H]1c1nc2ccc(cc2s1)-c1cncnc1)N1CCCCCC1 IUYCHWWTZJSDJO-SAABIXHNSA-N 0.000 description 3
UUEAVOVBHVTANJ-KTDGPJBASA-N CC1CCCN1[C@H]1C[C@@H](C1)c1nc2cc(ccc2s1)-c1ccc(C)nc1C Chemical compound CC1CCCN1[C@H]1C[C@@H](C1)c1nc2cc(ccc2s1)-c1ccc(C)nc1C UUEAVOVBHVTANJ-KTDGPJBASA-N 0.000 description 3
YIGZXFNBSVXLOC-SAABIXHNSA-N COc1ncc(cn1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCCC1 Chemical compound COc1ncc(cn1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCCC1 YIGZXFNBSVXLOC-SAABIXHNSA-N 0.000 description 3
AVMVFGOIPBJTGB-JCNLHEQBSA-N Cn1cc(cn1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCC1 Chemical compound Cn1cc(cn1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCC1 AVMVFGOIPBJTGB-JCNLHEQBSA-N 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
WJLODTRRDWCCOD-XFBNRCLWSA-N O=C1C(C)CCN1C1=CC=C(N=C(S2)[C@@H]3C[C@H](C3)N3CCCCC3)C2=C1 Chemical compound O=C1C(C)CCN1C1=CC=C(N=C(S2)[C@@H]3C[C@H](C3)N3CCCCC3)C2=C1 WJLODTRRDWCCOD-XFBNRCLWSA-N 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
229910004298 SiO 2 Inorganic materials 0.000 description 3
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
229920001615 Tragacanth Polymers 0.000 description 3
KFHYZKCRXNRKRC-MRXNPFEDSA-N abt-239 Chemical compound C[C@@H]1CCCN1CCC1=CC2=CC(C=3C=CC(=CC=3)C#N)=CC=C2O1 KFHYZKCRXNRKRC-MRXNPFEDSA-N 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
230000004913 activation Effects 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
235000010419 agar Nutrition 0.000 description 3
125000003282 alkyl amino group Chemical group 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
235000010233 benzoic acid Nutrition 0.000 description 3
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 3
NNTOJPXOCKCMKR-UHFFFAOYSA-N boron;pyridine Chemical compound [B].C1=CC=NC=C1 NNTOJPXOCKCMKR-UHFFFAOYSA-N 0.000 description 3
125000005620 boronic acid group Chemical class 0.000 description 3
239000000872 buffer Substances 0.000 description 3
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
150000001805 chlorine compounds Chemical class 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000000576 coating method Methods 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
238000001816 cooling Methods 0.000 description 3
125000004122 cyclic group Chemical group 0.000 description 3
125000004663 dialkyl amino group Chemical group 0.000 description 3
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
125000000532 dioxanyl group Chemical group 0.000 description 3
208000037765 diseases and disorders Diseases 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
125000005883 dithianyl group Chemical group 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
239000000284 extract Substances 0.000 description 3
239000000945 filler Substances 0.000 description 3
230000037406 food intake Effects 0.000 description 3
235000012631 food intake Nutrition 0.000 description 3
239000000499 gel Substances 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
125000005843 halogen group Chemical group 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
230000007794 irritation Effects 0.000 description 3
238000002955 isolation Methods 0.000 description 3
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 3
239000008101 lactose Substances 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
239000012528 membrane Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
125000002950 monocyclic group Chemical group 0.000 description 3
239000002547 new drug Substances 0.000 description 3
239000002674 ointment Substances 0.000 description 3
150000007524 organic acids Chemical class 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
235000011007 phosphoric acid Nutrition 0.000 description 3
125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
230000002265 prevention Effects 0.000 description 3
229960004063 propylene glycol Drugs 0.000 description 3
125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 3
ABMYEXAYWZJVOV-UHFFFAOYSA-N pyridin-3-ylboronic acid Chemical compound OB(O)C1=CC=CN=C1 ABMYEXAYWZJVOV-UHFFFAOYSA-N 0.000 description 3
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 3
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 3
230000002285 radioactive effect Effects 0.000 description 3
229940044551 receptor antagonist Drugs 0.000 description 3
239000002464 receptor antagonist Substances 0.000 description 3
238000010992 reflux Methods 0.000 description 3
125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 3
238000000926 separation method Methods 0.000 description 3
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 3
239000007909 solid dosage form Substances 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
125000004434 sulfur atom Chemical group 0.000 description 3
239000000829 suppository Substances 0.000 description 3
239000000375 suspending agent Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
235000012222 talc Nutrition 0.000 description 3
238000012360 testing method Methods 0.000 description 3
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 3
125000001412 tetrahydropyranyl group Chemical group 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
235000010487 tragacanth Nutrition 0.000 description 3
239000000196 tragacanth Substances 0.000 description 3
229940116362 tragacanth Drugs 0.000 description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 3
DLQYXUGCCKQSRJ-UHFFFAOYSA-N tris(furan-2-yl)phosphane Chemical compound C1=COC(P(C=2OC=CC=2)C=2OC=CC=2)=C1 DLQYXUGCCKQSRJ-UHFFFAOYSA-N 0.000 description 3
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
NVOLYUXUHWBCRJ-UHFFFAOYSA-N (2-methoxypyridin-3-yl)boronic acid Chemical group COC1=NC=CC=C1B(O)O NVOLYUXUHWBCRJ-UHFFFAOYSA-N 0.000 description 2
AVAOHVDRAKDFRF-KLPPUMKISA-N (2r,3r)-2,3-dihydroxybutanedioic acid;(2r)-2-methylpyrrolidine Chemical compound C[C@@H]1CCCN1.OC(=O)[C@H](O)[C@@H](O)C(O)=O AVAOHVDRAKDFRF-KLPPUMKISA-N 0.000 description 2
RGHPCLZJAFCTIK-YFKPBYRVSA-N (2s)-2-methylpyrrolidine Chemical compound C[C@H]1CCCN1 RGHPCLZJAFCTIK-YFKPBYRVSA-N 0.000 description 2
VLECDMDGMKPUSK-NUBCRITNSA-N (3r)-piperidin-3-ol;hydrochloride Chemical compound Cl.O[C@@H]1CCCNC1 VLECDMDGMKPUSK-NUBCRITNSA-N 0.000 description 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
SKHNRJKSLVTZJH-UHFFFAOYSA-N 2,6-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound CC1=NC(C)=CC=C1B1OC(C)(C)C(C)(C)O1 SKHNRJKSLVTZJH-UHFFFAOYSA-N 0.000 description 2
GGHTXOCGORMRRT-UHFFFAOYSA-N 2-(3-piperidin-1-ylcyclobutyl)-n-pyrimidin-2-yl-1,3-benzothiazol-6-amine Chemical compound C1C(N2CCCCC2)CC1C(SC1=C2)=NC1=CC=C2NC1=NC=CC=N1 GGHTXOCGORMRRT-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
VRVRGVPWCUEOGV-UHFFFAOYSA-N 2-aminothiophenol Chemical class NC1=CC=CC=C1S VRVRGVPWCUEOGV-UHFFFAOYSA-N 0.000 description 2
OFTKFKYVSBNYEC-UHFFFAOYSA-N 2-furoyl chloride Chemical compound ClC(=O)C1=CC=CO1 OFTKFKYVSBNYEC-UHFFFAOYSA-N 0.000 description 2
YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 2
BRUZQRBVNRKLJG-UHFFFAOYSA-N 2-methylpropyl carbamate Chemical compound CC(C)COC(N)=O BRUZQRBVNRKLJG-UHFFFAOYSA-N 0.000 description 2
ANRUJJLGVODXIK-UHFFFAOYSA-N 3-amino-N-[2-(1H-imidazol-5-yl)ethyl]propanamide Chemical compound NCCC(=O)NCCC1=CN=CN1 ANRUJJLGVODXIK-UHFFFAOYSA-N 0.000 description 2
NNKLICLIBKMDOY-UHFFFAOYSA-N 3-methylidenecyclobutane-1-carboxylic acid Chemical class OC(=O)C1CC(=C)C1 NNKLICLIBKMDOY-UHFFFAOYSA-N 0.000 description 2
USEDMAWWQDFMFY-UHFFFAOYSA-N 4-cyanobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(C#N)C=C1 USEDMAWWQDFMFY-UHFFFAOYSA-N 0.000 description 2
YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
LLRDOWMENSWEOD-UHFFFAOYSA-N 6-[[2-(3-piperidin-1-ylcyclobutyl)-1,3-benzothiazol-6-yl]amino]pyridine-3-carbonitrile Chemical compound N1=CC(C#N)=CC=C1NC1=CC=C(N=C(S2)C3CC(C3)N3CCCCC3)C2=C1 LLRDOWMENSWEOD-UHFFFAOYSA-N 0.000 description 2
IZBFPESQPDJSIX-UHFFFAOYSA-N 6-bromo-2-[3-(pyrrolidin-1-ylmethyl)cyclobutyl]-1,3-benzothiazole Chemical compound S1C2=CC(Br)=CC=C2N=C1C(C1)CC1CN1CCCC1 IZBFPESQPDJSIX-UHFFFAOYSA-N 0.000 description 2
HECJMTPEVWQFCY-UHFFFAOYSA-N 6-bromo-3h-1,3-benzothiazol-2-one Chemical compound BrC1=CC=C2NC(=O)SC2=C1 HECJMTPEVWQFCY-UHFFFAOYSA-N 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
BGTRGCOPISVADT-KOMQPUFPSA-N C1[C@@H](C[C@H]1c1nc2ccc(cc2s1)-c1cncnc1)N1CCOCC1 Chemical compound C1[C@@H](C[C@H]1c1nc2ccc(cc2s1)-c1cncnc1)N1CCOCC1 BGTRGCOPISVADT-KOMQPUFPSA-N 0.000 description 2
NTPURGHJURCDFZ-JCNLHEQBSA-N CC(C)COC(=O)Nc1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCC1 Chemical compound CC(C)COC(=O)Nc1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCC1 NTPURGHJURCDFZ-JCNLHEQBSA-N 0.000 description 2
SMIAYHPWCLZKHP-JNHYILFESA-N CC1CCCN1[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-c1cnn(C)c1 Chemical compound CC1CCCN1[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-c1cnn(C)c1 SMIAYHPWCLZKHP-JNHYILFESA-N 0.000 description 2
XVDHBQYRAQWBTF-UMSPYCQHSA-N CCN(CC)[C@H]1C[C@@H](C1)c1nc2ccc(Br)cc2s1 Chemical compound CCN(CC)[C@H]1C[C@@H](C1)c1nc2ccc(Br)cc2s1 XVDHBQYRAQWBTF-UMSPYCQHSA-N 0.000 description 2
ULPUFTGKTHVRTQ-QAQDUYKDSA-N COc1ccc(cn1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N(C)C(C)C Chemical compound COc1ccc(cn1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N(C)C(C)C ULPUFTGKTHVRTQ-QAQDUYKDSA-N 0.000 description 2
BORQIBSWTPRMTR-ZTFGCOKTSA-N COc1ccc(cn1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCC[C@H]1C Chemical compound COc1ccc(cn1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCC[C@H]1C BORQIBSWTPRMTR-ZTFGCOKTSA-N 0.000 description 2
NKKBHGLKUYJDBR-KOMQPUFPSA-N COc1ncc(cn1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N(C)C(C)C Chemical compound COc1ncc(cn1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N(C)C(C)C NKKBHGLKUYJDBR-KOMQPUFPSA-N 0.000 description 2
ORVDRYBNKZAGKA-KOMQPUFPSA-N COc1ncc(cn1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCC1 Chemical compound COc1ncc(cn1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCC1 ORVDRYBNKZAGKA-KOMQPUFPSA-N 0.000 description 2
OIJYBNGGVYJUPB-WKILWMFISA-N COc1ncccc1-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N(C)C(C)C Chemical compound COc1ncccc1-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N(C)C(C)C OIJYBNGGVYJUPB-WKILWMFISA-N 0.000 description 2
VENZFXGKLDWKDJ-ZTFGCOKTSA-N C[C@@H]1CCCN1[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-c1ccncc1 Chemical compound C[C@@H]1CCCN1[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-c1ccncc1 VENZFXGKLDWKDJ-ZTFGCOKTSA-N 0.000 description 2
NQCDFKOCADODLY-OZOXKJRCSA-N C[C@@H]1CCCN1[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-c1cnc2ccccc2c1 Chemical compound C[C@@H]1CCCN1[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-c1cnc2ccccc2c1 NQCDFKOCADODLY-OZOXKJRCSA-N 0.000 description 2
NQCDFKOCADODLY-LRQRDZAKSA-N C[C@H]1CCCN1[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-c1cnc2ccccc2c1 Chemical compound C[C@H]1CCCN1[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-c1cnc2ccccc2c1 NQCDFKOCADODLY-LRQRDZAKSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
239000004215 Carbon black (E152) Substances 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
NZLFEFJKVQDALO-FHWLQOOXSA-N Cc1ccc(c(C)n1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCC[C@H]1CO Chemical compound Cc1ccc(c(C)n1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCC[C@H]1CO NZLFEFJKVQDALO-FHWLQOOXSA-N 0.000 description 2
SXZOVPVHAGJFFO-CZIWCDLHSA-N Cn1cc(cn1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCC(F)CC1 Chemical compound Cn1cc(cn1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCC(F)CC1 SXZOVPVHAGJFFO-CZIWCDLHSA-N 0.000 description 2
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
241000206672 Gelidium Species 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
208000027601 Inner ear disease Diseases 0.000 description 2
208000031773 Insulin resistance syndrome Diseases 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
206010029333 Neurosis Diseases 0.000 description 2
LRKAWGIZLGMQIX-KOMQPUFPSA-N O=C(Nc1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCC1)C1CC1 Chemical compound O=C(Nc1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCC1)C1CC1 LRKAWGIZLGMQIX-KOMQPUFPSA-N 0.000 description 2
PVGISPNSLADMEW-KOMQPUFPSA-N O=C1N(C)CCN1C1=CC=C(N=C(S2)[C@@H]3C[C@H](C3)N3CCCCC3)C2=C1 Chemical compound O=C1N(C)CCN1C1=CC=C(N=C(S2)[C@@H]3C[C@H](C3)N3CCCCC3)C2=C1 PVGISPNSLADMEW-KOMQPUFPSA-N 0.000 description 2
FTRQEGABGCOFEN-CTYIDZIISA-N O=C1OCCN1C1=CC=C(N=C(S2)[C@@H]3C[C@H](C3)N3CCCCC3)C2=C1 Chemical compound O=C1OCCN1C1=CC=C(N=C(S2)[C@@H]3C[C@H](C3)N3CCCCC3)C2=C1 FTRQEGABGCOFEN-CTYIDZIISA-N 0.000 description 2
DWCVMBFAAUGDQT-XIRDDKMYSA-N OC[C@@H]1CCCN1[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-c1cncnc1 Chemical compound OC[C@@H]1CCCN1[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-c1cncnc1 DWCVMBFAAUGDQT-XIRDDKMYSA-N 0.000 description 2
URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 2
235000019483 Peanut oil Nutrition 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
206010036049 Polycystic ovaries Diseases 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
241000700157 Rattus norvegicus Species 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
206010041349 Somnolence Diseases 0.000 description 2
ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 2
208000000323 Tourette Syndrome Diseases 0.000 description 2
208000016620 Tourette disease Diseases 0.000 description 2
208000012886 Vertigo Diseases 0.000 description 2
XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
150000001266 acyl halides Chemical class 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
150000001299 aldehydes Chemical class 0.000 description 2
239000000783 alginic acid Substances 0.000 description 2
229960001126 alginic acid Drugs 0.000 description 2
150000004781 alginic acids Chemical class 0.000 description 2
150000003973 alkyl amines Chemical class 0.000 description 2
150000001350 alkyl halides Chemical class 0.000 description 2
KCNKJCHARANTIP-SNAWJCMRSA-N allyl-{4-[3-(4-bromo-phenyl)-benzofuran-6-yloxy]-but-2-enyl}-methyl-amine Chemical compound C=1OC2=CC(OC/C=C/CN(CC=C)C)=CC=C2C=1C1=CC=C(Br)C=C1 KCNKJCHARANTIP-SNAWJCMRSA-N 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
229940025084 amphetamine Drugs 0.000 description 2
150000008064 anhydrides Chemical class 0.000 description 2
MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
125000003710 aryl alkyl group Chemical group 0.000 description 2
150000001502 aryl halides Chemical class 0.000 description 2
ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 2
239000000440 bentonite Substances 0.000 description 2
229910000278 bentonite Inorganic materials 0.000 description 2
235000012216 bentonite Nutrition 0.000 description 2
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
125000005605 benzo group Chemical group 0.000 description 2
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
230000037396 body weight Effects 0.000 description 2
UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
150000001642 boronic acid derivatives Chemical class 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
150000001649 bromium compounds Chemical class 0.000 description 2
239000006172 buffering agent Substances 0.000 description 2
244000309464 bull Species 0.000 description 2
235000019437 butane-1,3-diol Nutrition 0.000 description 2
FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
229910000024 caesium carbonate Inorganic materials 0.000 description 2
YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
108700021352 carcinine Proteins 0.000 description 2
230000009084 cardiovascular function Effects 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
SYGWYBOJXOGMRU-UHFFFAOYSA-N chembl233051 Chemical compound C1=CC=C2C3=CC(C(N(CCN(C)C)C4=O)=O)=C5C4=CC=CC5=C3SC2=C1 SYGWYBOJXOGMRU-UHFFFAOYSA-N 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
229940110456 cocoa butter Drugs 0.000 description 2
235000019868 cocoa butter Nutrition 0.000 description 2
235000005687 corn oil Nutrition 0.000 description 2
239000002285 corn oil Substances 0.000 description 2
235000012343 cottonseed oil Nutrition 0.000 description 2
239000002385 cottonseed oil Substances 0.000 description 2
239000006071 cream Substances 0.000 description 2
125000006254 cycloalkyl carbonyl group Chemical group 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
238000002059 diagnostic imaging Methods 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 2
SXZIXHOMFPUIRK-UHFFFAOYSA-N diphenylmethanimine Chemical compound C=1C=CC=CC=1C(=N)C1=CC=CC=C1 SXZIXHOMFPUIRK-UHFFFAOYSA-N 0.000 description 2
230000006806 disease prevention Effects 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
238000004821 distillation Methods 0.000 description 2
229960003638 dopamine Drugs 0.000 description 2
230000004064 dysfunction Effects 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
230000001804 emulsifying effect Effects 0.000 description 2
239000003885 eye ointment Substances 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
125000001153 fluoro group Chemical group F* 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
230000006870 function Effects 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
238000007429 general method Methods 0.000 description 2
239000008103 glucose Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
229930195733 hydrocarbon Natural products 0.000 description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
YXOKBHUPEBNZOG-UHFFFAOYSA-N hydron;4-hydroxy-7-[2-[2-[3-(2-phenylethoxy)propylsulfonyl]ethylamino]ethyl]-3h-1,3-benzothiazol-2-one;chloride Chemical compound Cl.C1=2SC(=O)NC=2C(O)=CC=C1CCNCCS(=O)(=O)CCCOCCC1=CC=CC=C1 YXOKBHUPEBNZOG-UHFFFAOYSA-N 0.000 description 2
230000002267 hypothalamic effect Effects 0.000 description 2
238000003384 imaging method Methods 0.000 description 2
150000002466 imines Chemical class 0.000 description 2
125000001841 imino group Chemical group [H]N=* 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000003993 interaction Effects 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
150000004694 iodide salts Chemical class 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000010410 layer Substances 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
239000008297 liquid dosage form Substances 0.000 description 2
229910052744 lithium Inorganic materials 0.000 description 2
230000006742 locomotor activity Effects 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
238000001819 mass spectrum Methods 0.000 description 2
239000002609 medium Substances 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
239000004530 micro-emulsion Substances 0.000 description 2
208000027061 mild cognitive impairment Diseases 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
230000007510 mood change Effects 0.000 description 2
STUHQDIOZQUPGP-UHFFFAOYSA-N morpholin-4-ium-4-carboxylate Chemical compound OC(=O)N1CCOCC1 STUHQDIOZQUPGP-UHFFFAOYSA-N 0.000 description 2
GJZPOLSRRDGRQC-UHFFFAOYSA-N n-(5-bromopyrimidin-2-yl)-2-(3-piperidin-1-ylcyclobutyl)-1,3-benzothiazol-6-amine Chemical compound N1=CC(Br)=CN=C1NC1=CC=C(N=C(S2)C3CC(C3)N3CCCCC3)C2=C1 GJZPOLSRRDGRQC-UHFFFAOYSA-N 0.000 description 2
IZEMPRRIKYABEX-UHFFFAOYSA-N n-(5-methylpyridin-2-yl)-2-(3-piperidin-1-ylcyclobutyl)-1,3-benzothiazol-6-amine Chemical compound N1=CC(C)=CC=C1NC1=CC=C(N=C(S2)C3CC(C3)N3CCCCC3)C2=C1 IZEMPRRIKYABEX-UHFFFAOYSA-N 0.000 description 2
GVWISOJSERXQBM-UHFFFAOYSA-N n-methylpropan-1-amine Chemical compound CCCNC GVWISOJSERXQBM-UHFFFAOYSA-N 0.000 description 2
XHFGWHUWQXTGAT-UHFFFAOYSA-N n-methylpropan-2-amine Chemical compound CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 2
210000005036 nerve Anatomy 0.000 description 2
208000004296 neuralgia Diseases 0.000 description 2
230000003705 neurological process Effects 0.000 description 2
210000002569 neuron Anatomy 0.000 description 2
208000021722 neuropathic pain Diseases 0.000 description 2
201000001119 neuropathy Diseases 0.000 description 2
230000007823 neuropathy Effects 0.000 description 2
208000015238 neurotic disease Diseases 0.000 description 2
239000012299 nitrogen atmosphere Substances 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
125000001715 oxadiazolyl group Chemical group 0.000 description 2
239000004031 partial agonist Substances 0.000 description 2
239000006072 paste Substances 0.000 description 2
239000000312 peanut oil Substances 0.000 description 2
125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 2
208000033808 peripheral neuropathy Diseases 0.000 description 2
YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 2
BIWOSRSKDCZIFM-UHFFFAOYSA-N piperidin-3-ol Chemical compound OC1CCCNC1 BIWOSRSKDCZIFM-UHFFFAOYSA-N 0.000 description 2
HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 2
IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 2
201000010065 polycystic ovary syndrome Diseases 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000011591 potassium Substances 0.000 description 2
NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
239000011698 potassium fluoride Substances 0.000 description 2
239000003380 propellant Substances 0.000 description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
238000000159 protein binding assay Methods 0.000 description 2
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
238000012552 review Methods 0.000 description 2
150000003335 secondary amines Chemical group 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
239000012279 sodium borohydride Substances 0.000 description 2
229910000033 sodium borohydride Inorganic materials 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
229910000104 sodium hydride Inorganic materials 0.000 description 2
235000019333 sodium laurylsulphate Nutrition 0.000 description 2
JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
PIOSEDPFJPAJKQ-UHFFFAOYSA-M sodium;toluene;hydroxide Chemical compound [OH-].[Na+].CC1=CC=CC=C1 PIOSEDPFJPAJKQ-UHFFFAOYSA-M 0.000 description 2
239000008247 solid mixture Substances 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
238000012453 sprague-dawley rat model Methods 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000008223 sterile water Substances 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
229940095064 tartrate Drugs 0.000 description 2
IZPYBIJFRFWRPR-UHFFFAOYSA-N tert-butyl pyrrole-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C=CC=C1 IZPYBIJFRFWRPR-UHFFFAOYSA-N 0.000 description 2
238000011285 therapeutic regimen Methods 0.000 description 2
125000001113 thiadiazolyl group Chemical group 0.000 description 2
125000004568 thiomorpholinyl group Chemical group 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
231100000889 vertigo Toxicity 0.000 description 2
208000027491 vestibular disease Diseases 0.000 description 2
VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
RYGOBSYXIIUFOR-UHFFFAOYSA-N (1-methylpyrazol-4-yl)boronic acid Chemical compound CN1C=C(B(O)O)C=N1 RYGOBSYXIIUFOR-UHFFFAOYSA-N 0.000 description 1
NNWUEBIEOFQMSS-ZCFIWIBFSA-N (2r)-2-methylpiperidine Chemical compound C[C@@H]1CCCCN1 NNWUEBIEOFQMSS-ZCFIWIBFSA-N 0.000 description 1
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
WMCKMBIRRGZGLE-YFKPBYRVSA-N (2s)-2-(fluoromethyl)pyrrolidine Chemical compound FC[C@@H]1CCCN1 WMCKMBIRRGZGLE-YFKPBYRVSA-N 0.000 description 1
NNWUEBIEOFQMSS-LURJTMIESA-N (2s)-2-methylpiperidine Chemical compound C[C@H]1CCCCN1 NNWUEBIEOFQMSS-LURJTMIESA-N 0.000 description 1
BMQDAIUNAGXSKR-UHFFFAOYSA-N (3-hydroxy-2,3-dimethylbutan-2-yl)oxyboronic acid Chemical compound CC(C)(O)C(C)(C)OB(O)O BMQDAIUNAGXSKR-UHFFFAOYSA-N 0.000 description 1
MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
CEBAHYWORUOILU-UHFFFAOYSA-N (4-cyanophenyl)boronic acid Chemical compound OB(O)C1=CC=C(C#N)C=C1 CEBAHYWORUOILU-UHFFFAOYSA-N 0.000 description 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 description 1
HEVMDQBCAHEHDY-UHFFFAOYSA-N (Dimethoxymethyl)benzene Chemical compound COC(OC)C1=CC=CC=C1 HEVMDQBCAHEHDY-UHFFFAOYSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
HNGBKGXXEVZGIE-UHFFFAOYSA-N 1,3-benzothiazole;cyclobutanamine Chemical class NC1CCC1.C1=CC=C2SC=NC2=C1 HNGBKGXXEVZGIE-UHFFFAOYSA-N 0.000 description 1
229940058015 1,3-butylene glycol Drugs 0.000 description 1
AICIYIDUYNFPRY-UHFFFAOYSA-N 1,3-dihydro-2H-imidazol-2-one Chemical compound O=C1NC=CN1 AICIYIDUYNFPRY-UHFFFAOYSA-N 0.000 description 1
RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 1
OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 1
125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
WLUBCWHNODUIFZ-UHFFFAOYSA-N 1-chloro-3-methylidenecyclobutane-1-carbonitrile Chemical compound N#CC1(Cl)CC(=C)C1 WLUBCWHNODUIFZ-UHFFFAOYSA-N 0.000 description 1
VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
DCWSIGMEQOMJMR-UHFFFAOYSA-N 1-hydroxy-3-methylidenecyclobutane-1-carboxylic acid Chemical compound OC(=O)C1(O)CC(=C)C1 DCWSIGMEQOMJMR-UHFFFAOYSA-N 0.000 description 1
BWFQEOQVRYWZSG-UHFFFAOYSA-N 1-methyl-3-methylidenecyclobutane-1-carbonitrile Chemical compound N#CC1(C)CC(=C)C1 BWFQEOQVRYWZSG-UHFFFAOYSA-N 0.000 description 1
IDHHSXMRNXRQSW-UHFFFAOYSA-N 1-methyl-3-methylidenecyclobutane-1-carboxylic acid Chemical compound OC(=O)C1(C)CC(=C)C1 IDHHSXMRNXRQSW-UHFFFAOYSA-N 0.000 description 1
UCNGGGYMLHAMJG-UHFFFAOYSA-N 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound C1=NN(C)C=C1B1OC(C)(C)C(C)(C)O1 UCNGGGYMLHAMJG-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
125000003562 2,2-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical group CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
WMCKMBIRRGZGLE-UHFFFAOYSA-N 2-(fluoromethyl)pyrrolidine Chemical compound FCC1CCCN1 WMCKMBIRRGZGLE-UHFFFAOYSA-N 0.000 description 1
125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
KCYBHHLXWJWORQ-UHFFFAOYSA-N 2-[2-(3-oxocyclobutyl)-1,3-benzothiazol-6-yl]pyridazin-3-one Chemical compound C1C(=O)CC1C1=NC2=CC=C(N3C(C=CC=N3)=O)C=C2S1 KCYBHHLXWJWORQ-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
NGIRMPARLVGMPX-UHFFFAOYSA-N 2-amino-4-chlorobenzenethiol Chemical compound NC1=CC(Cl)=CC=C1S NGIRMPARLVGMPX-UHFFFAOYSA-N 0.000 description 1
BQEKAJKGQIHWHD-UHFFFAOYSA-N 2-amino-5-(dimethylamino)benzenethiol Chemical compound CN(C)C1=CC=C(N)C(S)=C1 BQEKAJKGQIHWHD-UHFFFAOYSA-N 0.000 description 1
WJNRRJVYIOBHJF-UHFFFAOYSA-N 2-amino-5-anilinobenzenethiol Chemical compound C1=C(S)C(N)=CC=C1NC1=CC=CC=C1 WJNRRJVYIOBHJF-UHFFFAOYSA-N 0.000 description 1
LDGHLZFFKMEAOE-UHFFFAOYSA-N 2-amino-5-bromobenzenethiol Chemical compound NC1=CC=C(Br)C=C1S LDGHLZFFKMEAOE-UHFFFAOYSA-N 0.000 description 1
KWCYELBAYUBCNS-UHFFFAOYSA-N 2-amino-5-ethoxybenzenethiol Chemical compound CCOC1=CC=C(N)C(S)=C1 KWCYELBAYUBCNS-UHFFFAOYSA-N 0.000 description 1
125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
TYWPDVVKWKYPFW-UHFFFAOYSA-N 2-phenyl-1,3-benzothiazole-5-carboxylic acid Chemical compound N=1C2=CC(C(=O)O)=CC=C2SC=1C1=CC=CC=C1 TYWPDVVKWKYPFW-UHFFFAOYSA-N 0.000 description 1
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
AJYXPNIENRLELY-UHFFFAOYSA-N 2-thiophen-2-ylacetyl chloride Chemical compound ClC(=O)CC1=CC=CS1 AJYXPNIENRLELY-UHFFFAOYSA-N 0.000 description 1
RCNOGGGBSSVMAS-UHFFFAOYSA-N 2-thiophen-3-ylacetic acid Chemical compound OC(=O)CC=1C=CSC=1 RCNOGGGBSSVMAS-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
UBHYDQAARZKHEZ-RFLHHMENSA-N 3-(1h-imidazol-5-yl)propyl n'-[2-(4-iodanylphenyl)ethyl]carbamimidothioate Chemical compound C=1C=C([125I])C=CC=1CC/N=C(/N)SCCCC1=CN=CN1 UBHYDQAARZKHEZ-RFLHHMENSA-N 0.000 description 1
HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
ARRJAONCYUAPJR-UHFFFAOYSA-N 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN=C(C=CC=C2)C2=C1 ARRJAONCYUAPJR-UHFFFAOYSA-N 0.000 description 1
BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
ZMLOBPVPZZPHKH-UHFFFAOYSA-N 3-(6-bromo-1,3-benzothiazol-2-yl)cyclobutan-1-one Chemical compound S1C2=CC(Br)=CC=C2N=C1C1CC(=O)C1 ZMLOBPVPZZPHKH-UHFFFAOYSA-N 0.000 description 1
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
XLTJXJJMUFDQEZ-UHFFFAOYSA-N 3-(furan-2-yl)propanoic acid Chemical compound OC(=O)CCC1=CC=CO1 XLTJXJJMUFDQEZ-UHFFFAOYSA-N 0.000 description 1
WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
TUJVGHCSNXCAFE-UHFFFAOYSA-N 3-bromo-2,6-dimethylpyridine Chemical compound CC1=CC=C(Br)C(C)=N1 TUJVGHCSNXCAFE-UHFFFAOYSA-N 0.000 description 1
125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
AEKCXHAMCVJMIP-UHFFFAOYSA-N 3-methylidene-1-(trifluoromethyl)cyclobutane-1-carbonitrile Chemical compound FC(F)(F)C1(C#N)CC(=C)C1 AEKCXHAMCVJMIP-UHFFFAOYSA-N 0.000 description 1
AOCWQPKHSMJWPL-UHFFFAOYSA-N 3-methylpyrrolidin-2-one Chemical compound CC1CCNC1=O AOCWQPKHSMJWPL-UHFFFAOYSA-N 0.000 description 1
XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
MJPVYTKZYZPIQA-UHFFFAOYSA-N 3-thiophen-2-ylpropanoic acid Chemical compound OC(=O)CCC1=CC=CS1 MJPVYTKZYZPIQA-UHFFFAOYSA-N 0.000 description 1
CZWWCTHQXBMHDA-UHFFFAOYSA-N 3h-1,3-thiazol-2-one Chemical class OC1=NC=CS1 CZWWCTHQXBMHDA-UHFFFAOYSA-N 0.000 description 1
MRWWWZLJWNIEEJ-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-propan-2-yloxy-1,3,2-dioxaborolane Chemical compound CC(C)OB1OC(C)(C)C(C)(C)O1 MRWWWZLJWNIEEJ-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
NJVKYFHOQLLDHU-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-tritylpyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)N=C1 NJVKYFHOQLLDHU-UHFFFAOYSA-N 0.000 description 1
MXDAYVCCPKGPOE-UHFFFAOYSA-N 4-amino-3-sulfanylbenzonitrile Chemical compound NC1=CC=C(C#N)C=C1S MXDAYVCCPKGPOE-UHFFFAOYSA-N 0.000 description 1
KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
DBMFYTQPPBBKHI-UHFFFAOYSA-N 4-cyanobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C(C#N)C=C1 DBMFYTQPPBBKHI-UHFFFAOYSA-N 0.000 description 1
125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
IXENWFQXVCOHAZ-UHFFFAOYSA-N 4-fluoropiperidine;hydrochloride Chemical compound Cl.FC1CCNCC1 IXENWFQXVCOHAZ-UHFFFAOYSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 1
IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
UHRHPPKWXSNZLR-UHFFFAOYSA-N 5-bromopyrimidin-2-amine Chemical compound NC1=NC=C(Br)C=N1 UHRHPPKWXSNZLR-UHFFFAOYSA-N 0.000 description 1
GYCPLYCTMDTEPU-UHFFFAOYSA-N 5-bromopyrimidine Chemical compound BrC1=CN=CN=C1 GYCPLYCTMDTEPU-UHFFFAOYSA-N 0.000 description 1
QMGASQUWXHSAAH-UHFFFAOYSA-N 5-chloro-2-(3-methylidenecyclobutyl)-1,3-benzothiazole Chemical compound N=1C2=CC(Cl)=CC=C2SC=1C1CC(=C)C1 QMGASQUWXHSAAH-UHFFFAOYSA-N 0.000 description 1
AOOWZUZDIXWXDQ-UHFFFAOYSA-N 5-chloro-2-[3-(2-methylpyrrolidin-1-yl)cyclobutyl]-1,3-benzothiazole Chemical compound CC1CCCN1C1CC(C=2SC3=CC=C(Cl)C=C3N=2)C1 AOOWZUZDIXWXDQ-UHFFFAOYSA-N 0.000 description 1
NOVHYVKPKWACML-UHFFFAOYSA-N 5-chloro-3h-1,3-benzothiazol-2-one Chemical compound ClC1=CC=C2SC(O)=NC2=C1 NOVHYVKPKWACML-UHFFFAOYSA-N 0.000 description 1
125000006043 5-hexenyl group Chemical group 0.000 description 1
CMBSSVKZOPZBKW-UHFFFAOYSA-N 5-methylpyridin-2-amine Chemical compound CC1=CC=C(N)N=C1 CMBSSVKZOPZBKW-UHFFFAOYSA-N 0.000 description 1
XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
WTFUTSCZYYCBAY-SXBRIOAWSA-N 6-[(E)-C-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-N-hydroxycarbonimidoyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C/C(=N/O)/C1=CC2=C(NC(O2)=O)C=C1 WTFUTSCZYYCBAY-SXBRIOAWSA-N 0.000 description 1
LLQHSBBZNDXTIV-UHFFFAOYSA-N 6-[5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-4,5-dihydro-1,2-oxazol-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC1CC(=NO1)C1=CC2=C(NC(O2)=O)C=C1 LLQHSBBZNDXTIV-UHFFFAOYSA-N 0.000 description 1
XAXDHTLQCLSNER-UHFFFAOYSA-N 6-bromo-2-(3-methylidenecyclobutyl)-1,3-benzothiazole Chemical compound S1C2=CC(Br)=CC=C2N=C1C1CC(=C)C1 XAXDHTLQCLSNER-UHFFFAOYSA-N 0.000 description 1
HQULYFAKUZDRPB-UHFFFAOYSA-N 6-bromo-2-[4-(trifluoromethoxy)phenoxy]-1,3-benzothiazole Chemical compound BrC1=CC2=C(N=C(S2)OC2=CC=C(C=C2)OC(F)(F)F)C=C1 HQULYFAKUZDRPB-UHFFFAOYSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
241001439211 Almeida Species 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
QCNACZSMRPJTIX-UHFFFAOYSA-N Br.OCCS(O)(=O)=O Chemical compound Br.OCCS(O)(=O)=O QCNACZSMRPJTIX-UHFFFAOYSA-N 0.000 description 1
NMRPBOQZHBSCHR-XYPYZODXSA-N BrC1=CC2=C(N=C(S2)[C@@H]2C[C@H](C2)CCNCCO)C=C1 Chemical compound BrC1=CC2=C(N=C(S2)[C@@H]2C[C@H](C2)CCNCCO)C=C1 NMRPBOQZHBSCHR-XYPYZODXSA-N 0.000 description 1
LLANNBJOSJBUNX-HOMQSWHASA-N Brc1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCC1 Chemical compound Brc1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCC1 LLANNBJOSJBUNX-HOMQSWHASA-N 0.000 description 1
ORWVDSVHLNWYHQ-UMSPYCQHSA-N Brc1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCC1 Chemical compound Brc1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCC1 ORWVDSVHLNWYHQ-UMSPYCQHSA-N 0.000 description 1
WOFPKTNECUCGPU-MQMHXKEQSA-N Brc1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCCC1 Chemical compound Brc1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCCC1 WOFPKTNECUCGPU-MQMHXKEQSA-N 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 description 1
NHLJSBMMWQNDIM-KOMQPUFPSA-N C1[C@@H](C[C@H]1c1nc2ccc(cc2s1)-c1cn[nH]c1)N1CCCCC1 Chemical compound C1[C@@H](C[C@H]1c1nc2ccc(cc2s1)-c1cn[nH]c1)N1CCCCC1 NHLJSBMMWQNDIM-KOMQPUFPSA-N 0.000 description 1
RJGSJQMSYCAAID-UMSPYCQHSA-N CC(C)N(C)[C@H]1C[C@@H](C1)c1nc2ccc(Br)cc2s1 Chemical compound CC(C)N(C)[C@H]1C[C@@H](C1)c1nc2ccc(Br)cc2s1 RJGSJQMSYCAAID-UMSPYCQHSA-N 0.000 description 1
QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
JMBFZXQTHAWLGL-KOMQPUFPSA-N CCN(CC)[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-c1cnc(OC)nc1 Chemical compound CCN(CC)[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-c1cnc(OC)nc1 JMBFZXQTHAWLGL-KOMQPUFPSA-N 0.000 description 1
KBETWXKFUJGXAP-KOMQPUFPSA-N CCN(CCO)[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-c1cnc(OC)nc1 Chemical compound CCN(CCO)[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-c1cnc(OC)nc1 KBETWXKFUJGXAP-KOMQPUFPSA-N 0.000 description 1
INUKRHLDYLJCBZ-OBJOEFQTSA-N C[C@H]1CCCCN1[C@@H]1C[C@@H](C=2SC3=CC(Br)=CC=C3N=2)C1 Chemical compound C[C@H]1CCCCN1[C@@H]1C[C@@H](C=2SC3=CC(Br)=CC=C3N=2)C1 INUKRHLDYLJCBZ-OBJOEFQTSA-N 0.000 description 1
ABXPYCIUPKSNPM-GVXVVHGQSA-N C[C@H]1CCCN1[C@H]1C[C@@H](C1)c1nc2ccc(Br)cc2s1 Chemical compound C[C@H]1CCCN1[C@H]1C[C@@H](C1)c1nc2ccc(Br)cc2s1 ABXPYCIUPKSNPM-GVXVVHGQSA-N 0.000 description 1
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
FPZMHMLIXRFUIG-MXVIHJGJSA-N Cc1ccc(c(C)n1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCCC1 Chemical compound Cc1ccc(c(C)n1)-c1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCCC1 FPZMHMLIXRFUIG-MXVIHJGJSA-N 0.000 description 1
OIMBMIGGGSMRMK-SAABIXHNSA-N Cc1cccn(-c2ccc3nc(sc3c2)[C@H]2C[C@@H](C2)N2CCCCC2)c1=O Chemical compound Cc1cccn(-c2ccc3nc(sc3c2)[C@H]2C[C@@H](C2)N2CCCCC2)c1=O OIMBMIGGGSMRMK-SAABIXHNSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
241000723346 Cinnamomum camphora Species 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
208000028698 Cognitive impairment Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
229940098778 Dopamine receptor agonist Drugs 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
239000004606 Fillers/Extenders Substances 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
230000010558 Gene Alterations Effects 0.000 description 1
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
102000003834 Histamine H1 Receptors Human genes 0.000 description 1
108090000110 Histamine H1 Receptors Proteins 0.000 description 1
101001016833 Homo sapiens Histamine H3 receptor Proteins 0.000 description 1
101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 description 1
LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
238000006809 Jones oxidation reaction Methods 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
208000020358 Learning disease Diseases 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
239000012359 Methanesulfonyl chloride Substances 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
206010027940 Mood altered Diseases 0.000 description 1
208000016285 Movement disease Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
206010028735 Nasal congestion Diseases 0.000 description 1
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
SEZHDNUPRWMIGC-JCNLHEQBSA-N O=C(Nc1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCC1)C1CCC1 Chemical compound O=C(Nc1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCC1)C1CCC1 SEZHDNUPRWMIGC-JCNLHEQBSA-N 0.000 description 1
LKGSHVKKPKLPTO-SAABIXHNSA-N O=C(Nc1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCC1)C1CCCC1 Chemical compound O=C(Nc1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCC1)C1CCCC1 LKGSHVKKPKLPTO-SAABIXHNSA-N 0.000 description 1
AQRBBDWVRGAFRE-UAPYVXQJSA-N O=C(Nc1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCC1)C1CCCCC1 Chemical compound O=C(Nc1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCC1)C1CCCCC1 AQRBBDWVRGAFRE-UAPYVXQJSA-N 0.000 description 1
IRHIWIKXSWYGLW-KOMQPUFPSA-N O=C(Nc1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCC1)c1ccco1 Chemical compound O=C(Nc1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCC1)c1ccco1 IRHIWIKXSWYGLW-KOMQPUFPSA-N 0.000 description 1
VXUDVAJFSYZSNW-KOMQPUFPSA-N O=C(Nc1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCC1)c1cnccn1 Chemical compound O=C(Nc1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCC1)c1cnccn1 VXUDVAJFSYZSNW-KOMQPUFPSA-N 0.000 description 1
UHSHCVMPSOVMFZ-CZIWCDLHSA-N O=C(Nc1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCC1)c1cncnc1 Chemical compound O=C(Nc1ccc2nc(sc2c1)[C@H]1C[C@@H](C1)N1CCCCC1)c1cncnc1 UHSHCVMPSOVMFZ-CZIWCDLHSA-N 0.000 description 1
QMDFXKJRXDAWFO-MQMHXKEQSA-N OCC1CCN(CC1)[C@H]1C[C@@H](C1)c1nc2ccc(Br)cc2s1 Chemical compound OCC1CCN(CC1)[C@H]1C[C@@H](C1)c1nc2ccc(Br)cc2s1 QMDFXKJRXDAWFO-MQMHXKEQSA-N 0.000 description 1
IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
OJZSBMIGYJNMLL-DRZSPHRISA-N OC[C@@H]1CCCN1[C@H]1C[C@@H](C1)c1nc2ccc(Br)cc2s1 Chemical compound OC[C@@H]1CCCN1[C@H]1C[C@@H](C1)c1nc2ccc(Br)cc2s1 OJZSBMIGYJNMLL-DRZSPHRISA-N 0.000 description 1
BVVCQHIWXUFURU-DJIMGWMZSA-N O[C@@H]1CCCN(C1)[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-c1cncnc1 Chemical compound O[C@@H]1CCCN(C1)[C@H]1C[C@@H](C1)c1nc2ccc(cc2s1)-c1cncnc1 BVVCQHIWXUFURU-DJIMGWMZSA-N 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
108010088847 Peptide YY Proteins 0.000 description 1
102100029909 Peptide YY Human genes 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
229920002873 Polyethylenimine Polymers 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
101001016835 Rattus norvegicus Histamine H3 receptor Proteins 0.000 description 1
102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
208000032140 Sleepiness Diseases 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
102000001494 Sterol O-Acyltransferase Human genes 0.000 description 1
108010054082 Sterol O-acyltransferase Proteins 0.000 description 1
238000006619 Stille reaction Methods 0.000 description 1
238000006859 Swern oxidation reaction Methods 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 1
LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
HVVNJUAVDAZWCB-YFKPBYRVSA-N [(2s)-pyrrolidin-2-yl]methanol Chemical compound OC[C@@H]1CCCN1 HVVNJUAVDAZWCB-YFKPBYRVSA-N 0.000 description 1
SHCYZVIEVXYFON-UHFFFAOYSA-N [3-(6-bromo-1,3-benzothiazol-2-yl)cyclobutyl]methanol Chemical compound C1C(CO)CC1C1=NC2=CC=C(Br)C=C2S1 SHCYZVIEVXYFON-UHFFFAOYSA-N 0.000 description 1
OHBFCJRSEWUPBT-MUCZFFFMSA-N [4-[4-[3-[(2r,5r)-2,5-dimethylpyrrolidin-1-yl]propoxy]phenyl]phenyl]-morpholin-4-ylmethanone;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C[C@@H]1CC[C@@H](C)N1CCCOC1=CC=C(C=2C=CC(=CC=2)C(=O)N2CCOCC2)C=C1 OHBFCJRSEWUPBT-MUCZFFFMSA-N 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
239000003655 absorption accelerator Substances 0.000 description 1
239000003070 absorption delaying agent Substances 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
229960004373 acetylcholine Drugs 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
230000001800 adrenalinergic effect Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001343 alkyl silanes Chemical group 0.000 description 1
125000005087 alkynylcarbonyl group Chemical group 0.000 description 1
201000009961 allergic asthma Diseases 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000003579 anti-obesity Effects 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
239000003693 atypical antipsychotic agent Substances 0.000 description 1
JNDBWGDXMCXJPM-UHFFFAOYSA-N azane;2-phenylethanamine Chemical class N.NCCC1=CC=CC=C1 JNDBWGDXMCXJPM-UHFFFAOYSA-N 0.000 description 1
PCFAAFDUVZFFCH-UHFFFAOYSA-N azane;pyrrolidine Chemical class N.C1CCNC1 PCFAAFDUVZFFCH-UHFFFAOYSA-N 0.000 description 1
125000003828 azulenyl group Chemical group 0.000 description 1
230000006399 behavior Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
MYONAGGJKCJOBT-UHFFFAOYSA-N benzimidazol-2-one Chemical compound C1=CC=CC2=NC(=O)N=C21 MYONAGGJKCJOBT-UHFFFAOYSA-N 0.000 description 1
229940050390 benzoate Drugs 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
229960002903 benzyl benzoate Drugs 0.000 description 1
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
229940073608 benzyl chloride Drugs 0.000 description 1
HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
239000004621 biodegradable polymer Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
239000000090 biomarker Substances 0.000 description 1
230000036983 biotransformation Effects 0.000 description 1
239000012455 biphasic mixture Substances 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
229910000085 borane Inorganic materials 0.000 description 1
UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
125000006309 butyl amino group Chemical group 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000012241 calcium silicate Nutrition 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
229960000846 camphor Drugs 0.000 description 1
229930008380 camphor Natural products 0.000 description 1
MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
235000017663 capsaicin Nutrition 0.000 description 1
229960002504 capsaicin Drugs 0.000 description 1
150000004657 carbamic acid derivatives Chemical class 0.000 description 1
235000013877 carbamide Nutrition 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
125000004181 carboxyalkyl group Chemical group 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
229940000032 cardiovascular system drug Drugs 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
230000001713 cholinergic effect Effects 0.000 description 1
229940001468 citrate Drugs 0.000 description 1
239000004927 clay Substances 0.000 description 1
QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
229960004170 clozapine Drugs 0.000 description 1
239000002361 compost Substances 0.000 description 1
238000013329 compounding Methods 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
125000004966 cyanoalkyl group Chemical group 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
150000005676 cyclic carbonates Chemical class 0.000 description 1
238000006352 cycloaddition reaction Methods 0.000 description 1
125000000392 cycloalkenyl group Chemical group 0.000 description 1
MFNYBOWJWGPXFM-UHFFFAOYSA-N cyclobutanecarboxamide Chemical compound NC(=O)C1CCC1 MFNYBOWJWGPXFM-UHFFFAOYSA-N 0.000 description 1
150000001930 cyclobutanes Chemical class 0.000 description 1
KTHXBEHDVMTNOH-UHFFFAOYSA-N cyclobutanol Chemical compound OC1CCC1 KTHXBEHDVMTNOH-UHFFFAOYSA-N 0.000 description 1
RVOJTCZRIKWHDX-UHFFFAOYSA-N cyclohexanecarbonyl chloride Chemical compound ClC(=O)C1CCCCC1 RVOJTCZRIKWHDX-UHFFFAOYSA-N 0.000 description 1
125000006639 cyclohexyl carbonyl group Chemical group 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
125000006638 cyclopentyl carbonyl group Chemical group 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
ACQBHJXEAYTHCY-UHFFFAOYSA-N cyclopropyl-[4-[3-(1H-imidazol-5-yl)propoxy]phenyl]methanone Chemical compound C=1C=C(OCCCC=2NC=NC=2)C=CC=1C(=O)C1CC1 ACQBHJXEAYTHCY-UHFFFAOYSA-N 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
239000012024 dehydrating agents‎ Substances 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
PBGGNZZGJIKBMJ-UHFFFAOYSA-N di(propan-2-yl)azanide Chemical compound CC(C)[N-]C(C)C PBGGNZZGJIKBMJ-UHFFFAOYSA-N 0.000 description 1
125000005265 dialkylamine group Chemical group 0.000 description 1
150000004985 diamines Chemical class 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
125000004639 dihydroindenyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
239000000539 dimer Substances 0.000 description 1
IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 description 1
GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 1
FWISSTYMWZFAHN-UHFFFAOYSA-N disodium methanolate Chemical compound [Na+].[Na+].C[O-].C[O-] FWISSTYMWZFAHN-UHFFFAOYSA-N 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
LBOJYSIDWZQNJS-CVEARBPZSA-N dizocilpine Chemical compound C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 LBOJYSIDWZQNJS-CVEARBPZSA-N 0.000 description 1
229950004794 dizocilpine Drugs 0.000 description 1
QLTXKCWMEZIHBJ-PJGJYSAQSA-N dizocilpine maleate Chemical compound OC(=O)\C=C/C(O)=O.C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 QLTXKCWMEZIHBJ-PJGJYSAQSA-N 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
239000006196 drop Substances 0.000 description 1
238000009510 drug design Methods 0.000 description 1
238000009509 drug development Methods 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000003221 ear drop Substances 0.000 description 1
229940047652 ear drops Drugs 0.000 description 1
150000002081 enamines Chemical class 0.000 description 1
239000006274 endogenous ligand Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
229940093499 ethyl acetate Drugs 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 1
125000006125 ethylsulfonyl group Chemical group 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
150000002222 fluorine compounds Chemical class 0.000 description 1
125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
NHGVZTMBVDFPHJ-UHFFFAOYSA-N formyl fluoride Chemical compound FC=O NHGVZTMBVDFPHJ-UHFFFAOYSA-N 0.000 description 1
239000003205 fragrance Substances 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000000417 fungicide Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
238000000227 grinding Methods 0.000 description 1
150000002366 halogen compounds Chemical class 0.000 description 1
230000036541 health Effects 0.000 description 1
MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
150000002391 heterocyclic compounds Chemical class 0.000 description 1
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
239000003382 histamine H3 receptor agonist Substances 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
239000012456 homogeneous solution Substances 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
239000003906 humectant Substances 0.000 description 1
150000004678 hydrides Chemical class 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
229910052738 indium Inorganic materials 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
229940102213 injectable suspension Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229940125425 inverse agonist Drugs 0.000 description 1
238000011835 investigation Methods 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
239000011630 iodine Chemical group 0.000 description 1
PCEBAZIVZVIQEO-UHFFFAOYSA-N iodocyclopentane Chemical compound IC1CCCC1 PCEBAZIVZVIQEO-UHFFFAOYSA-N 0.000 description 1
HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
XJTQJERLRPWUGL-UHFFFAOYSA-N iodomethylbenzene Chemical compound ICC1=CC=CC=C1 XJTQJERLRPWUGL-UHFFFAOYSA-N 0.000 description 1
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
229940047889 isobutyramide Drugs 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
PTKHFRNHJULJKT-UHFFFAOYSA-N jnj-5207852 Chemical compound C1CCCCN1CCCOC(C=C1)=CC=C1CN1CCCCC1 PTKHFRNHJULJKT-UHFFFAOYSA-N 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
201000003723 learning disability Diseases 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000004973 liquid crystal related substance Substances 0.000 description 1
238000005567 liquid scintillation counting Methods 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
239000000347 magnesium hydroxide Substances 0.000 description 1
229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000005056 memory consolidation Effects 0.000 description 1
TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 1
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
ZCKPTTBRWYHPOT-UHFFFAOYSA-N methyl 3-amino-4-sulfanylbenzoate Chemical compound COC(=O)C1=CC=C(S)C(N)=C1 ZCKPTTBRWYHPOT-UHFFFAOYSA-N 0.000 description 1
125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 1
125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
244000005700 microbiome Species 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
239000002808 molecular sieve Substances 0.000 description 1
CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
XMWFMEYDRNJSOO-UHFFFAOYSA-N morpholine-4-carbonyl chloride Chemical compound ClC(=O)N1CCOCC1 XMWFMEYDRNJSOO-UHFFFAOYSA-N 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
229940051866 mouthwash Drugs 0.000 description 1
125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
XCVNDBIXFPGMIW-UHFFFAOYSA-N n-ethylpropan-1-amine Chemical compound CCCNCC XCVNDBIXFPGMIW-UHFFFAOYSA-N 0.000 description 1
125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
UHNHTTIUNATJKL-UHFFFAOYSA-N n-methylmethanesulfonamide Chemical compound CNS(C)(=O)=O UHNHTTIUNATJKL-UHFFFAOYSA-N 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000006252 n-propylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
210000005170 neoplastic cell Anatomy 0.000 description 1
210000004126 nerve fiber Anatomy 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000002895 organic esters Chemical class 0.000 description 1
125000001979 organolithium group Chemical group 0.000 description 1
229910052762 osmium Inorganic materials 0.000 description 1
SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000007310 pathophysiology Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
239000002304 perfume Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
FHHJDRFHHWUPDG-UHFFFAOYSA-N peroxysulfuric acid Chemical compound OOS(O)(=O)=O FHHJDRFHHWUPDG-UHFFFAOYSA-N 0.000 description 1
239000012071 phase Substances 0.000 description 1
125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
150000008105 phosphatidylcholines Chemical class 0.000 description 1
XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
229940075930 picrate Drugs 0.000 description 1
OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
229950010765 pivalate Drugs 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000003270 potassium fluoride Nutrition 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
230000006977 prepulse inhibition Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
UFUASNAHBMBJIX-UHFFFAOYSA-N propan-1-one Chemical group CC[C]=O UFUASNAHBMBJIX-UHFFFAOYSA-N 0.000 description 1
238000010926 purge Methods 0.000 description 1
QLULGIRFKAWHOJ-UHFFFAOYSA-N pyridin-4-ylboronic acid Chemical compound OB(O)C1=CC=NC=C1 QLULGIRFKAWHOJ-UHFFFAOYSA-N 0.000 description 1
HZFPPBMKGYINDF-UHFFFAOYSA-N pyrimidin-5-ylboronic acid Chemical compound OB(O)C1=CN=CN=C1 HZFPPBMKGYINDF-UHFFFAOYSA-N 0.000 description 1
QOTUIIJRVXKSJU-UHFFFAOYSA-N pyrrolidin-3-ylmethanol Chemical compound OCC1CCNC1 QOTUIIJRVXKSJU-UHFFFAOYSA-N 0.000 description 1
150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
238000010791 quenching Methods 0.000 description 1
230000000171 quenching effect Effects 0.000 description 1
230000005855 radiation Effects 0.000 description 1
108700042226 ras Genes Proteins 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000005057 refrigeration Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000012827 research and development Methods 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
239000003340 retarding agent Substances 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
125000006413 ring segment Chemical group 0.000 description 1
239000004576 sand Substances 0.000 description 1
229930195734 saturated hydrocarbon Natural products 0.000 description 1
STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
229960002646 scopolamine Drugs 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
210000002265 sensory receptor cell Anatomy 0.000 description 1
230000000862 serotonergic effect Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
230000011664 signaling Effects 0.000 description 1
238000010898 silica gel chromatography Methods 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
239000010703 silicon Substances 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
208000020685 sleep-wake disease Diseases 0.000 description 1
230000037321 sleepiness Effects 0.000 description 1
239000002002 slurry Substances 0.000 description 1
AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
SYXYWTXQFUUWLP-UHFFFAOYSA-N sodium;butan-1-olate Chemical compound [Na+].CCCC[O-] SYXYWTXQFUUWLP-UHFFFAOYSA-N 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
238000011699 spontaneously hypertensive rat Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000003206 sterilizing agent Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000005062 synaptic transmission Effects 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
VNNLHYZDXIBHKZ-UHFFFAOYSA-N thiophene-2-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CS1 VNNLHYZDXIBHKZ-UHFFFAOYSA-N 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
239000012485 toluene extract Substances 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
QQJLHRRUATVHED-UHFFFAOYSA-N tramazoline Chemical compound N1CCN=C1NC1=CC=CC2=C1CCCC2 QQJLHRRUATVHED-UHFFFAOYSA-N 0.000 description 1
229960001262 tramazoline Drugs 0.000 description 1
238000000844 transformation Methods 0.000 description 1
TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
STMPXDBGVJZCEX-UHFFFAOYSA-N triethylsilyl trifluoromethanesulfonate Chemical compound CC[Si](CC)(CC)OS(=O)(=O)C(F)(F)F STMPXDBGVJZCEX-UHFFFAOYSA-N 0.000 description 1
150000008648 triflates Chemical class 0.000 description 1
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
239000010681 turmeric oil Substances 0.000 description 1
230000007306 turnover Effects 0.000 description 1
150000003672 ureas Chemical class 0.000 description 1
238000003828 vacuum filtration Methods 0.000 description 1
238000002061 vacuum sublimation Methods 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
210000004440 vestibular nuclei Anatomy 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
239000008096 xylene Substances 0.000 description 1
239000011787 zinc oxide Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Pulmonology (AREA)
Reproductive Health (AREA)
Addiction (AREA)
Psychology (AREA)
Pregnancy & Childbirth (AREA)
Anesthesiology (AREA)
Child & Adolescent Psychology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Gynecology & Obstetrics (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Epidemiology (AREA)

BRPI0616146-4A 2005-09-22 2006-09-19 derivados benzotiazol ciclobutil amina e seu uso como ligantes dos receptores de histamina-3 BRPI0616146A2 (pt)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US71951605P	2005-09-22	2005-09-22
US60/719,516		2005-09-22
US11/518,132		2006-09-08
US11/518,132 US7576110B2 (en)	2005-09-22	2006-09-08	Benzothiazole cyclobutyl amine derivatives
PCT/US2006/036422 WO2007038074A1 (en)	2005-09-22	2006-09-19	Benzothiazole cyclobutyl amine derivatives and their use as histamine-3 receptors ligands

Publications (1)

Publication Number	Publication Date
BRPI0616146A2 true BRPI0616146A2 (pt)	2011-06-07

Family

ID=37885027

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0616146-4A BRPI0616146A2 (pt)	2005-09-22	2006-09-19	derivados benzotiazol ciclobutil amina e seu uso como ligantes dos receptores de histamina-3

Country Status (25)

Country	Link
US (2)	US7576110B2 (sr)
EP (2)	EP2386556B1 (sr)
JP (1)	JP2009508957A (sr)
KR (1)	KR20080050628A (sr)
AT (1)	ATE538119T1 (sr)
AU (1)	AU2006295065C1 (sr)
BR (1)	BRPI0616146A2 (sr)
CA (1)	CA2623252A1 (sr)
CR (1)	CR9822A (sr)
CY (1)	CY1112727T1 (sr)
DK (1)	DK1926729T3 (sr)
EC (1)	ECSP088326A (sr)
ES (1)	ES2378197T3 (sr)
HR (2)	HRP20080174A2 (sr)
IL (1)	IL190350A (sr)
MY (2)	MY150990A (sr)
NO (1)	NO20081905L (sr)
NZ (1)	NZ566834A (sr)
PL (1)	PL1926729T3 (sr)
PT (1)	PT1926729E (sr)
RS (1)	RS52231B (sr)
SI (1)	SI1926729T1 (sr)
TW (1)	TWI393717B (sr)
WO (1)	WO2007038074A1 (sr)
ZA (1)	ZA200802508B (sr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7576110B2 (en) *	2005-09-22	2009-08-18	Abbott Laboratories	Benzothiazole cyclobutyl amine derivatives
CA2655604C (en) *	2006-06-23	2016-08-09	Abbott Laboratories	Cyclopropyl amine derivatives
US9108948B2 (en) *	2006-06-23	2015-08-18	Abbvie Inc.	Cyclopropyl amine derivatives
EA200901378A1 (ru) *	2007-04-19	2010-04-30	Юсб Фарма С.А.	Лиганды гистаминового рецептора н, содержащие циклобутоксигруппу
US8153813B2 (en)	2007-12-20	2012-04-10	Abbott Laboratories	Benzothiazole and benzooxazole derivatives and methods of use
US8383657B2 (en) *	2007-12-21	2013-02-26	Abbott Laboratories	Thiazolylidine urea and amide derivatives and methods of use thereof
US20090221648A1 (en) *	2007-12-21	2009-09-03	Abbott Laboratories	Compositions for treatment of cognitive disorders
EA201001205A1 (ru) *	2008-01-24	2011-04-29	Юсб Фарма, С.А.	Соединения, содержащие циклобутоксигруппу
KR100986433B1 (ko)	2008-05-30	2010-10-08	현대자동차주식회사	전동식 파워스티어링 시스템
US9186353B2 (en) *	2009-04-27	2015-11-17	Abbvie Inc.	Treatment of osteoarthritis pain
US8853390B2 (en)	2010-09-16	2014-10-07	Abbvie Inc.	Processes for preparing 1,2-substituted cyclopropyl derivatives
BR112015031155A2 (pt)	2013-06-20	2017-07-25	Bayer Cropscience Ag	derivados de sulfureto de arila e derivados de aril sulfóxido como acaricidas e inseticidas
EP4151627A1 (en)	2017-06-05	2023-03-22	PTC Therapeutics, Inc.	Compounds for treating huntington's disease
BR112020019373A2 (pt)	2018-03-27	2020-12-29	Ptc Therapeutics, Inc.	Compostos para o tratamento da doença de hutington
KR20210038845A (ko)	2018-06-27	2021-04-08	피티씨 테라퓨틱스, 인크.	헌팅턴병 치료를 위한 헤테로아릴 화합물
CA3139821A1 (en)	2019-05-13	2020-11-19	Ptc Therapeutics, Inc.	Compounds for treating huntington's disease
WO2021222366A1 (en) *	2020-04-28	2021-11-04	Kymera Therapeutics, Inc.	Irak inhibitors and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US171181A (en) *		1875-12-14		Improvement in fence-posts
US224952A (en) *		1880-02-24		Nventor
US78133A (en) *		1868-05-19		Improvement in heuometebs
DE491224C (de)	1923-05-20	1930-02-22	Leopold Cassella & Co G M B H	Verfahren zur Darstellung von Arylaminosubstitutionsprodukten von o-Aminoarylmercaptanen
GB8621790D0 (en)	1986-09-10	1986-10-15	Ici Plc	Tertiary amine compounds
GB9300194D0 (en)	1993-01-06	1993-03-03	Wyeth John & Brother Ltd	Piperazine derivatives
UA71945C2 (en)	1999-01-27	2005-01-17	Pfizer Prod Inc	Substituted bicyclic derivatives being used as anticancer agents
RU2174505C1 (ru)	2000-02-18	2001-10-10	Открытое акционерное общество "Всероссийский научно-исследовательский институт органического синтеза"	Способ получения функционально замещенного метиленциклобутана
DE10155202A1 (de) *	2001-11-09	2003-07-31	Boehringer Ingelheim Int	Herstellung und Verwendung von substituierten Imidazolen
US20030131975A1 (en) *	2002-01-11	2003-07-17	Sabina Houle	Integrated heat spreader with mechanical interlock designs
CA2765093A1 (en)	2002-11-12	2004-05-27	Abbott Laboratories	Bicyclic-substituted amines as histamine-3 receptor ligands
US20040224952A1 (en)	2003-05-07	2004-11-11	Cowart Marlon D.	Fused bicyclic-substituted amines as histamine-3 receptor ligands
EP1720847A1 (en)	2004-02-02	2006-11-15	Pfizer Products Incorporated	Histamine-3 receptor modulators
ES2371774T3 (es)	2005-06-03	2012-01-10	Abbott Laboratories	Derivados de ciclobutilamina.
US7576110B2 (en) *	2005-09-22	2009-08-18	Abbott Laboratories	Benzothiazole cyclobutyl amine derivatives

2006
- 2006-09-08 US US11/518,132 patent/US7576110B2/en active Active
- 2006-09-19 NZ NZ566834A patent/NZ566834A/en not_active IP Right Cessation
- 2006-09-19 ES ES06814914T patent/ES2378197T3/es active Active
- 2006-09-19 EP EP11165455.4A patent/EP2386556B1/en active Active
- 2006-09-19 EP EP06814914A patent/EP1926729B1/en active Active
- 2006-09-19 SI SI200631280T patent/SI1926729T1/sl unknown
- 2006-09-19 KR KR1020087009662A patent/KR20080050628A/ko not_active Ceased
- 2006-09-19 MY MYPI20114346 patent/MY150990A/en unknown
- 2006-09-19 DK DK06814914.5T patent/DK1926729T3/da active
- 2006-09-19 WO PCT/US2006/036422 patent/WO2007038074A1/en not_active Ceased
- 2006-09-19 CA CA002623252A patent/CA2623252A1/en not_active Abandoned
- 2006-09-19 BR BRPI0616146-4A patent/BRPI0616146A2/pt not_active IP Right Cessation
- 2006-09-19 PT PT06814914T patent/PT1926729E/pt unknown
- 2006-09-19 HR HR20080174A patent/HRP20080174A2/xx not_active Application Discontinuation
- 2006-09-19 AT AT06814914T patent/ATE538119T1/de active
- 2006-09-19 PL PL06814914T patent/PL1926729T3/pl unknown
- 2006-09-19 HR HRP20120251TT patent/HRP20120251T1/hr unknown
- 2006-09-19 AU AU2006295065A patent/AU2006295065C1/en not_active Ceased
- 2006-09-19 JP JP2008532313A patent/JP2009508957A/ja not_active Ceased
- 2006-09-19 RS RS20120112A patent/RS52231B/sr unknown
- 2006-09-19 MY MYPI20080763A patent/MY146028A/en unknown
- 2006-09-21 TW TW095135007A patent/TWI393717B/zh not_active IP Right Cessation
2008
- 2008-03-18 ZA ZA2008/02508A patent/ZA200802508B/en unknown
- 2008-03-20 IL IL190350A patent/IL190350A/en not_active IP Right Cessation
- 2008-03-24 CR CR9822A patent/CR9822A/es unknown
- 2008-03-28 EC EC2008008326A patent/ECSP088326A/es unknown
- 2008-04-22 NO NO20081905A patent/NO20081905L/no not_active Application Discontinuation
2009
- 2009-06-22 US US12/489,269 patent/US8592467B2/en not_active Expired - Fee Related
2012
- 2012-03-16 CY CY20121100283T patent/CY1112727T1/el unknown

Also Published As

Publication number	Publication date
US8592467B2 (en)	2013-11-26
MY150990A (en)	2014-03-31
US20090326222A1 (en)	2009-12-31
RS52231B (sr)	2012-10-31
TW200745098A (en)	2007-12-16
ZA200802508B (en)	2012-09-26
EP2386556B1 (en)	2013-10-23
SI1926729T1 (sl)	2012-04-30
HRP20080174A2 (hr)	2008-12-31
US20070066588A1 (en)	2007-03-22
JP2009508957A (ja)	2009-03-05
US7576110B2 (en)	2009-08-18
ATE538119T1 (de)	2012-01-15
HK1118291A1 (en)	2009-02-06
CA2623252A1 (en)	2007-04-05
NO20081905L (no)	2008-06-23
IL190350A0 (en)	2009-09-22
DK1926729T3 (da)	2012-03-19
IL190350A (en)	2013-08-29
WO2007038074A1 (en)	2007-04-05
KR20080050628A (ko)	2008-06-09
ES2378197T3 (es)	2012-04-09
CR9822A (es)	2008-08-01
TWI393717B (zh)	2013-04-21
NZ566834A (en)	2011-08-26
EP1926729A1 (en)	2008-06-04
AU2006295065A1 (en)	2007-04-05
CY1112727T1 (el)	2016-02-10
ECSP088326A (es)	2008-04-28
RU2008115313A (ru)	2009-10-27
PL1926729T3 (pl)	2012-05-31
AU2006295065C1 (en)	2012-11-22
EP1926729B1 (en)	2011-12-21
EP2386556A1 (en)	2011-11-16
PT1926729E (pt)	2012-03-27
MY146028A (en)	2012-06-15
AU2006295065B2 (en)	2012-03-08
HRP20120251T1 (hr)	2012-07-31

Legal Events

Date	Code	Title	Description
2014-05-06	B25A	Requested transfer of rights approved	Owner name: ABBVIE INC. (US)
2015-07-21	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 9A ANUIDADE.
2015-11-24	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2324 DE 21-07-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
US8592467B2 (en)	2013-11-26	Benzothiazole cyclobutyl amine derivatives
CN101951904A (zh)	2011-01-19	苯并噻唑和苯并*唑衍生物以及使用方法
JP5649975B2 (ja)	2015-01-07	シクロプロピルアミン誘導体
JP5203360B2 (ja)	2013-06-05	ヒスタミンｈ３受容体調節剤としてのシクロプロピルアミン誘導体
JP2008545751A (ja)	2008-12-18	シクロブチルアミン誘導体
RS56136B1 (sr)	2017-10-31	Jedinjenje guanidina
AU2012202812B2 (en)	2012-09-20	Benzothiazole cyclobutyl amine derivatives and their use as histamine-3 receptors ligands
CN101312966A (zh)	2008-11-26	苯并噻唑环丁胺衍生物及其作为组胺-3受体配体的应用
HK1164299A (en)	2012-09-21	Benzothiazole cyclobutyl amine derivatives and their use as histamine-3 receptors ligands
HK1118291B (en)	2012-05-18	Benzothiazole cyclobutyl amine derivatives and their use as histamine-3 receptors ligands
AU2012201625A1 (en)	2012-04-05	Cyclopropyl amine derivatives as histamin H3 receptor modulators